



Universiteit
Leiden
The Netherlands

Allosteric modulation and ligand binding kinetics at the Kv11.1 channel

Yu, Z.

Citation

Yu, Z. (2015, October 20). *Allosteric modulation and ligand binding kinetics at the Kv11.1 channel*. Retrieved from <https://hdl.handle.net/1887/35951>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/35951>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/35951> holds various files of this Leiden University dissertation.

Author: Yu, Zhiyi

Title: Allosteric modulation and ligand binding kinetics at the Kv11.1 channel

Issue Date: 2015-10-20

Chapter 5

Synthesis and biological evaluation of negative allosteric modulators of the K_v11.1 (hERG) channel

Zhiyi Yu
Jacobus P. D. van Veldhoven
Ingrid M. E. 't Hart
Adrian H. Kopf
Laura H. Heitman
Adriaan P. IJzerman

Abstract

We synthesized and evaluated a series of compounds for their allosteric modulation at the $K_v11.1$ (hERG) channel. Most compounds were negative allosteric modulators of [3H]dofetilide binding to the channel, in particular **7f**, **7h-j** and **7p**. Compounds **7f** and **7p** were the most potent negative allosteric modulators amongst all ligands, dramatically increasing the dissociation rate of dofetilide in the radioligand kinetic binding assay, while remarkably reducing the affinity of dofetilide and astemizole in a competitive displacement assay. Additionally, both **7f** and **7p** displayed peculiar displacement characteristics with Hill coefficients significantly distinct from unity as shown by e.g., dofetilide, further indicative of their allosteric effects on dofetilide binding. Our findings in this investigation yielded several promising negative allosteric modulators for future functional and clinical research with respect to their antiarrhythmic propensities, either alone or in combination with known $K_v11.1$ blockers.

Introduction

The past decades have witnessed an emerging interest in the identification of allosteric modulators of G protein-coupled receptors (GPCRs), ligand-gated ion channels (LGICs) and enzymes.¹⁻³ Allosteric modulators are ligands that bind to a binding site on a target protein that is not overlapping with and spatially distinct from the so-called orthosteric binding site, i.e. the site where e.g., hormones and neurotransmitters bind.⁴ Negative allosteric modulators reduce receptor binding and/or function associated with orthosteric ligands, whereas positive allosteric modulators enhance these.^{2,4,5} The therapeutic potential of allosteric modulators has been demonstrated in clinical trials, with a number of such drugs now on the market. Allosterically acting ligands provide novel opportunities for drug discovery due to a possible higher subtype-selectivity (allosteric sites are usually less conserved than orthosteric binding sites) and fewer side effects compared with traditional orthosteric compounds due to their ‘ceiling’ effect.^{2,3} However, research on the allosteric modulation of voltage-gated ion channels (VGICs) is largely lacking, in particular for the $K_v11.1$ (hERG) channel.

The $K_v11.1$ channel, encoded by the human ether-à-go-go-related gene (hERG), plays a vital role in regulating cardiac repolarization of the action potential of human ventricular myocytes.^{6,7} Genetic dysfunction or pharmacological inhibition of the $K_v11.1$ channel leads to prolongation of the action potential duration (APD), QT interval lengthening, and the development of Torsades de Pointes (TdP). A staggering array of drugs including antiarrhythmic agents, antihistamines, antibiotics and antipsychotics are known to block the $K_v11.1$ channel via a common, promiscuous binding region within the aqueous inner cavity of the pore.^{8,9} More recently, a small number of compounds, referred to as $K_v11.1$ activators, have been proposed to remediate repolarization disorders in the heart, including acquired and congenital long QT syndromes, due to their up-regulation of $K_v11.1$ currents.^{7,10,11} These activators were found to bind at sites that are distinct from each other and also different from the binding residues of prototypical $K_v11.1$ blockers.⁹ For instance, RPR260243 ((3*R*,4*R*)-4-[3-(6-methoxyquinolin-4-yl)-3-oxopropyl]-1-[3-(2,3,5-trifluorophenyl)prop-2ynyl]piperidine-3-carboxylic acid) that was designated as a type 1 activator interacted with a putative binding site at the cytoplasmic end facing away from the inner cavity of the channel, while type 2 activators like NS1643 (1,3-bis[2-hydroxy-5-(trifluoromethyl)phenyl]urea) appeared to interact with residues located on the outer mouth of the pore.^{8,12,13} Furthermore, some of these activators were found to reduce the affinity and subsequently reverse the action potential prolongation produced by $K_v11.1$ blockers. Pretreatment of cells expressing the $K_v11.1$

channel with RPR260243 slightly reduced the affinity of the reference hERG blocker dofetilide (*N*-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide), leading to a reduction of dofetilide's prolongation of the action potential.^{12, 14} Likewise, NS3623 (1-[4-bromo-2-(2*H*-tetrazol-5-yl)phenyl]-3-[3-(trifluoromethyl)phenyl]urea) produced a reversal of E-4031 (*N*-[4-[[1-[2-(6-Methyl-2-pyridinyl)ethyl]-4-piperidinyl]carbonyl]phenyl]methanesulfonamide dihydrochloride)-induced QT prolongation in both anaesthetized and conscious guinea pigs.¹⁵ In this sense, the so-called activators might be negative allosteric modulators of the action of $K_v11.1$ blockers, and so normalize the pharmacologically induced action potential prolongation. Indeed, the allosteric terminology at the $K_v11.1$ channel has been introduced in our previous study and a recent review.^{4, 16} Classic methods for screening allosteric modulators have been based on techniques used to identify $K_v11.1$ blockers, such as voltage-dependent fluorescence experiments and laborious patch clamp assays. However, these methods do not allow high throughput screening in the search for new hit and lead molecules.¹⁷ Moreover, although negative allosteric modulators of the $K_v11.1$ channel may be therapeutically promising, the current generation of modulators is not very potent and this raises concerns about their selectivity and liability for cardiac and non-cardiac side effects.^{9, 11} Therefore, it would be of particular importance to design and synthesize more novel allosteric modulators with higher potencies at the $K_v11.1$ channel.

Recently, Zhang *et al.* characterized a potent modulator (ML-T531, compound **7a** in this study) for the $K_v11.1$ channel after screening a large compound library using an automated electrophysiological technique, and found that it normalized APD prolongation induced by dysfunction of the $K_v7.1$ channel.¹⁸ This was the first experimental evidence that $K_v11.1$ modulators can prevent long QT type 1 (LQT1) in addition to type 2 (LQT2) syndrome. The concept that $K_v7.1$ and $K_v11.1$ activators can mutually rescue $K_v7.1$ -related LQT1 and $K_v11.1$ -induced LQT2 syndromes has been put forward previously, and was also validated by using a highly selective $K_v7.1$ modulator, R-L3 ((3*R*)-5-(2-fluorophenyl)-3-(1*H*-indol-3-ylmethyl)-1-methyl-3*H*-1,4-benzodiazepin-2-one)), which suppressed early afterdepolarizations initiated by the $K_v11.1$ blocker dofetilide in rabbit myocytes.^{17, 19, 20} Apart from ML-T531, a chemically similar compound (VU0405601, compound **7r**) was discovered in a fluorescence-based thallium influx assay, and this ligand allosterically diminished the affinity of dofetilide at the channel and relieved the arrhythmia induced by dofetilide.²¹ Altogether, negative allosteric modulators of the $K_v11.1$ channel could be beneficial in LQT syndromes induced by genetic loss-of-function or pharmacological inhibition of both $K_v11.1$ and $K_v7.1$ channels. In the present study, we selected ML-T531 and

VU0405601 as our starting point, and synthesized a series of new ligands with modifications at the three aromatic rings present in the basic scaffold of the lead compounds. Based on the results from a previously validated single point dissociation assay,¹⁶ their structure-activity relationships were analyzed. Subsequently, a selection of potent negative allosteric modulators were comprehensively characterized in [³H]dofetilide dissociation and displacement assays, and their influences on affinity of two specific K_v11.1 blockers (dofetilide and astemizole (1-[(4-fluorophenyl)methyl]-*N*-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidyl]benzimidazol-2-amine)) were evaluated as well.



Results and discussion

Chemistry

The synthetic route of all final compounds is depicted in **Scheme 1** except that compound **7r** was synthesized as previously described.²¹ Small systematic chemical variations were made by introducing different functional groups at the three aromatic rings of the reference compound (ML-T531, **7a**). Compounds based on modifications at the two phenyl rings (**7a-p**) were synthesized as follows. Friedel-Crafts acylation of substituted anisols (**1a-c**) and benzoyl chlorides (**2d-l** and **2n-p**) resulted in the formation of different substituted-benzophenone derivatives (**3b-l** and **3n-p**).²² Apart from acid chlorides **2o** and **2p** that were synthesized from the corresponding carboxylic acids **8o** and **8p** (**Scheme 2**), all other intermediates were commercially available. Demethylation of the methoxy group for compounds **3b-l** and **3n-p** with AlCl₃ or BBr₃ in the case of **3c** led to **4b-l** and **4n-p** with high yields (65-97%).^{22, 23} Notably, demethylation of **3c** using AlCl₃ conditions resulted in the undesired debrominated product **4a**. Subsequently, reaction of **4a-p** with 2-methylbromoacetate and hydrolysis of **5a-p** with LiOH produced compounds **6a-p**. Eventually, final compounds **7a-p** were obtained via a peptide coupling, using EDCI*HCl (**7e** and **7l**) or the superior HATU, between the acids (**6a-p**) and 3-aminopyridine in yields of 23-98%.²¹ Fluorenone analogue **7q** was synthesized as follows: i) an oxidative dehydrogenative cyclization of benzophenone **4a** resulted in fluorenone intermediate **4q**, and ii) subsequent HATU peptide coupling conditions led to the formation of final compound **7q**.²⁴ To further investigate the influences of the 3-pyridine ring on the allosteric modulation capacities of ligands, a variety of substituted 3-aminopyridines (**7f1-f8**) and other nitrogen-containing heterocyclic rings (**7f9-f11**) were synthesized in a similar approach as described above. All intermediates were commercially available except intermediate **10f5**, which was synthesized from 5-bromo-3-methoxy-


pyridine (**9f5**) through an amination using ammonia and copper sulphate pentahydrate (**Scheme 2**).²⁵

Scheme 1. Synthesis of compounds **7a-q** and **7f1-f11**.



a) AlCl_3 , DCM, 0 °C to r.t., 2 h; b) AlCl_3 , toluene, 130 °C, 2 h; c) 2-methylbromoacetate, K_2CO_3 , DMF, 65 °C, overnight; d) LiOH, THF, MeOH, 105 °C, 30 min; e) 3-aminopyridine, Et_3N , HATU or EDCI·HCl (**7e** and **7l**), DMF, overnight.


Scheme 2. Synthesis of intermediates (**2o**, **2p** and **10f5**)



a) SOCl_2 , 100 °C, 2h; b) NH_3 (aq), $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 140 °C, 20 h.

Structure-activity relationships

Initially, all synthesized compounds were tested for their abilities to increase or decrease the dissociation of [^3H]dofetilide from the HEK293K_v11.1 cell membrane preparations at 10 μM in a single point dissociation assay,¹⁶ and the results are summarized in **Table 1-3**. Compound **7a**, also referred to as ML-T531 in literature, has been reported to be the most potent K_v11.1 activator, which normalizes the prolonged APDs of patient-derived cardiomyocytes.¹⁸ Thus, a series of compounds with different substituents on the phenylcarbonyl ring were synthesized and evaluated for their allosteric modulation at the K_v11.1 channel (**Table 1**). Similar to compound **7a**, all compounds behaved as negative allosteric modulators of the K_v11.1 channel as they significantly increased the dissociation of dofetilide from the channel except **7l** and **7n**. The latter observation is in agreement with the previous finding that the effect of **7n** on K_v11.1 currents was insignificant and negligible,¹⁸ indicative of the reliability of our high-throughput single point dissociation assay. Introduction of halogens at the ortho position (**7d**, **7e** and **7g**) did not significantly impact the negative allosteric effect of the lead compound **7a**, whereas halogen substituents at the meta position (**7h-k**) displayed a more prominent enhancement of dofetilide dissociation compared to **7a**. Notably, introduction of a bromo substituent at the ortho position (**7f**) dramatically decreased the relative binding of dofetilide to $44 \pm 1\%$ from $78 \pm 3\%$ for **7a**, which implicated that ortho-bromo derivatives could be the starting point for designing more potent allosteric modulators of the K_v11.1 channel in the following step. With respect to the para position, methyl and chloro substituents (**7l** and **7n**) totally abolished the negative allosteric modulation properties of this series of compounds, while the 4-fluoro derivative slightly increased the allosteric effect (**7m** versus **7a**). The bigger size of the methyl and chloro substituents at the para-position may be the reason for this decrease in effect. Additionally, electron donating (**7l**) and withdrawing (**7n**) groups seemed to reduce the allosteric profiles of **7a** to the same extent, implying a negligible role of electronic effects in affecting allostery of compounds at the K_v11.1 channel. When bromo and fluoro substituents were simultaneously introduced to the ortho and meta positions, respectively, additional allosteric inhibition was observed for **7p** but **7o** exerted a much lower allosteric effect compared to compounds **7f** and **7h**. This confirms that steric hindrance at the phenyl ring might not be beneficial for the potency of these negative allosteric modulators.













Table 1. Allosteric modulation of [³H]dofetilide binding at the K_v11.1 channel by 10 μM of compounds **7a** and **7d-p**.


Compd	R	%B/B _{control}	Compd	R	%B/B _{control}
7a	H	78 ± 3	7j	3-Br	57 ± 5
7d	2-F	85 ± 4	7k	3-I	62 ± 3
7e	2-Cl	71 ± 2	7l	4-CH ₃	97 ± 5
7f	2-Br	44 ± 1	7m	4-F	65 ± 2
7g	2-I	72 ± 2	7n	4-Cl	104 ± 2
7h	3-F	47 ± 2	7o	2-Br, 3-F	85 ± 1
7i	3-Cl	43 ± 2	7p	2-Br, 5-F	38 ± 3

Since compounds with a bromo substituent (**7f** and **7p**) at the ortho position of the phenylcarbonyl ring were among the most potent modulators, a variety of compounds with the same ortho-bromo substitution but different nitrogen-containing heterocyclic aromatic rings were designed to investigate the influences of the pyridine moiety on allosteric modulation of the K_v11.1 channel. As displayed in **Table 2**, none of these compounds showed more prominent negative allosteric activities than the starting compound **7f**. By contrast, introduction of methyl, methoxyl, chlorine and phenyl groups amongst 3-pyridyl analogues (**7f1-f8**) abrogated the negative allosteric effects, and compounds **7f2** and **7f4** even appeared to decrease the dissociation of dofetilide albeit not significantly. It is worth noting that substituents with opposite electronic effects such as **7f1** and **7f3** could not be distinguished with respect to their allosteric activities, which is in agreement with our earlier finding for derivatives **7l** and **7n** shown in **Table 1**. This further proves that electronic effects were not the determinants of allosteric characteristics for this series of ligands. In addition, replacement of the pyridine ring with chlorine-substituted diazine (**7f9**), pyrimidine (**7f10**) and pyrazine (**7f11**) moieties led to significant decreases of the negative allosteric effects on the K_v11.1 channel compared to **7f**. Altogether, a non-substituted pyridine moiety is preferred for binding to the allosteric sites at the K_v11.1 channel. As compound **7r** (VU0405601) was found to significantly increase the IC₇₀ value of dofetilide and thus prevent its K_v11.1 inhibition,²¹ substituents at the phenolic ring were also explored in **Table 3**. Introducing bromine at the phenolic ring wholly eliminated their allosteric effects (**7b-c** versus **7a**), whereby linkage of the two phenyl rings






(**7q**) resulted in a comparably negative allosteric potency to the lead compound **7a**. Consistent with the previous publication,²¹ substitution of the general benzo-phenone moiety by a bromine-substituted naphthyl ring moderately increased the negative allosteric effect (**7r** versus **7a**).

Table 2. Allosteric modulation of [³H]dofetilide binding at the K_v11.1 channel by 10 μ M of compounds **7f1-f11**.

					
Compd	R	%B/B _{control}	Compd	R	%B/B _{control}
7f1		105 $\pm$ 12	7f7		105 $\pm$ 12
7f2		124 $\pm$ 13	7f8		87 $\pm$ 12
7f3		95 $\pm$ 12	7f9		92 $\pm$ 2
7f4		121 $\pm$ 15	7f10		87 $\pm$ 9
7f5		107 $\pm$ 15	7f11		92 $\pm$ 2
7f6		108 $\pm$ 16			

Taken together, all three aromatic rings played critical roles in modifying the allosteric effects of this series of compounds at the K_v11.1 channel. In general, introducing halogen substituents with comparatively less steric hindrance at the phenylcarbonyl ring, and avoiding substituents at the pyridine and phenolic rings were favorable for enhancing the negative allosteric potencies of these modulators. Among all compounds shown in **Table 1-3**, **7f**, **7i** and **7p** were the most potent negative allosteric modulators by reducing [³H]dofetilide binding during dissociation to 44 $\pm$ 1, 43 $\pm$ 2 and 38 $\pm$ 3% respectively, which demonstrated their higher potencies than reference compounds **7a** (78 $\pm$ 3%) and **7r** (66 $\pm$ 3%).

Table 3. Allosteric modulation of [³H]dofetilide binding at the K_v11.1 channel by 10 μM of compounds **7b**, **7c**, **7q** and **7r**.

					
Compd	R	%B/B _{control}	Compd	R	%B/B _{control}
7b		96 ± 1	7q		79 ± 6
7c		96 ± 7	7r		66 ± 3

Subsequently, several of the more potent allosteric modulators were selected in [³H]dofetilide dissociation and displacement assays to exploit their pharmacological characteristics at the K_v11.1 channel in more detail. Since the disintegration characteristics of a radioligand-receptor complex can only be altered by the binding of a compound to a site distinct from the radioligand binding site, the effects of these synthesized compounds on the dissociation rate of [³H]dofetilide can be unequivocally indicative of their allosteric actions.²⁶ In this respect, the dissociation behavior of [³H]dofetilide was investigated in the absence (control) or presence of potent modulators (**Figure 1** and **Table 4**). As concentration-dependent allosteric modulation has been observed in a plethora of receptors,^{5, 27-29} we evaluated a higher concentration (50 mM) of modulators in this assay, also to assess whether we could surpass the effects measured at 10 μM. The dissociation rate of the radioligand induced by an excess concentration of unlabeled dofetilide alone was 0.19 ± 0.01 min⁻¹, which was significantly increased by the selected compounds (**7f**, **7h-j** and **7p**), once more illustrating their negative allosteric modulation of the K_v11.1 channel. Compound **7p** was the most potent modulator that accelerated the k_{off} of dofetilide to 0.78 ± 0.20 min⁻¹, while **7j** was least efficacious with a dissociation rate of 0.27 ± 0.03 min⁻¹ for dofetilide. The ranking order of all five compounds in enhancing the dissociation rate of dofetilide was identical to the one obtained in the single point dissociation assay except for compound **7f**, which had a more prominent negative allosteric action in this assay. Next, the concentration-dependent effects of two representative compounds at increasing the dissociation of [³H]dofetilide from the K_v11.1 channel were assessed as in **Figure 2**, and the determined EC₅₀ values for **7f** and **7p** were 12 ± 2

and $4.6 \pm 0.4 \mu\text{M}$, respectively. This is in agreement with their activities in the other kinetic assays. It should be mentioned that a full concentration-effect curve of **7f** could not be recorded due to its limited solubility at higher concentrations. Furthermore, there was still 25% [^3H]dofetilide binding at the $\text{K}_{\text{v}}11.1$ channel left in the presence of $100 \mu\text{M}$ **7p**, which indicates that the binding of $\text{K}_{\text{v}}11.1$ blockers cannot be completely displaced via conformational changes of the channel caused by these negative allosteric modulators. More recently, curve-shifts that deviate from a simple competitive interaction at an equilibrium situation were revealed to be indicative of allostery.⁴ Consequently, we determined the effect of the potent modulators (**7f**, **7h-j** and **7p**) on the equilibrium affinity of two prototypical $\text{K}_{\text{v}}11.1$ blockers, dofetilide and astemizole (**Figure 3** and **Table 5**).




Figure 1. Dissociation curves of [^3H]dofetilide by $10 \mu\text{M}$ dofetilide in the absence (control) or presence of $50 \mu\text{M}$ **7f** and **7p**. Experiments were performed at 25°C with $20 \mu\text{g}$ HEK293 $\text{K}_{\text{v}}11.1$ membranes.

Table 4. Dissociation rates of [^3H]dofetilide in the absence (control) or presence of $50 \mu\text{M}$ **7f**, **7h-j** and **7p**, and EC_{50} values of two representative compounds (**7f** and **7p**) at accelerating dissociation of [^3H]dofetilide from the $\text{K}_{\text{v}}11.1$ channel.

Compd	$k_{\text{off, dofetilide}} (\text{min}^{-1})$	fold	$\text{EC}_{50} (\mu\text{M})$
control	0.19 ± 0.01	-	-
+ 7f	$0.57 \pm 0.05^{***}$	3.0	12 ± 2
+ 7h	$0.30 \pm 0.04^*$	1.6	-
+ 7i	$0.33 \pm 0.03^{**}$	1.7	-
+ 7j	$0.27 \pm 0.03^*$	1.4	-
+ 7p	$0.78 \pm 0.20^*$	4.1	4.6 ± 0.4

Values are means ($\pm$ SEM) of at least three independent experiments performed in duplicate (* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ versus control).




Figure 2. Concentration-dependent effects of **7f** and **7p** in accelerating dissociation of [³H]dofetilide from the K_v11.1 channel. Membrane proteins were first pre-equilibrated with [³H]dofetilide, then the dissociation was induced by 10 μM dofetilide in the absence or presence of different concentrations of compounds and the incubation was terminated after 6 min. The results are expressed as the ratio of the specific binding of [³H]dofetilide in the presence of 10 μM dofetilide plus various concentrations of negative allosteric modulators (*B*) over that in the presence of 10 μM dofetilide alone (*B_{control}*). Experiments were performed at 25 °C with 20 μg HEK293K_v11.1 membranes.

As shown in **Figure 3A** and **3B**, the displacement curves of both dofetilide and astemizole were right-ward shifted by compound **7f** and **7p** at 10 μM, which is another indication of the negative allosteric properties of **7f** and **7p**. The affinity of dofetilide ($K_i = 4.8 \pm 0.5$ nM) and astemizole ($K_i = 1.3 \pm 0.1$ nM) were comparable to our previous findings,³⁰ and their apparent K_i values were increased in the presence of all tested compounds. The K_i values of dofetilide shifted to 6.8 ± 0.5 nM (**7j**) and 22 ± 5 nM (**7p**), while the values for astemizole were 1.8 ± 0.5 nM (**7j**) and 8.2 ± 1.5 nM (**7p**). Apart from compound **7f**, the fold increase in K_i values for dofetilide and astemizole by these modulators was very comparable, and fully in line with our findings in the other dissociation assays. This diminishing of the affinity of K_v11.1 blockers through negative allosteric modulation is very appealing and may even help in mitigating acquired LQT syndromes via relieving drug-induced K_v11.1 blockade. The [³H]dofetilide equilibrium displacement curves of **7f** and **7p** shown in **Figure 4** were rather steep with pseudo Hill coefficients (-1.8 for both compounds) much larger than unity, further indicating their allosteric actions on dofetilide binding at the K_v11.1 channel.²⁹ For the sake of comparison, the displacement curve of dofetilide was also included in **Figure 4**, and the derived Hill slope was equal to -1.0 illustrating the competitive and ‘orthosteric’ binding of dofetilide and the reliability of this assay.




Figure 3. Displacement curves of dofetilide (**A**) and astemizole (**B**) in the absence (control) or presence of 10 μM **7f** and **7p** in a [^3H]dofetilide binding assay. Experiments were performed at 25 $^{\circ}\text{C}$ with 20 μg HEK293K_v11.1 membranes.

Table 5. The $K_{\text{v}}11.1$ affinities of dofetilide and astemizole in the absence (control) or presence of 10 μM **7f**, **7h-j** and **7p**.

Compd	$K_{\text{i, dofetilide}}$ (nM)	fold	$K_{\text{i, astemizole}}$ (nM)	fold
control	4.8 ± 0.5	-	1.3 ± 0.1	-
+ 7f	$12 \pm 3^*$	2.5	$5.3 \pm 1.3^*$	4.1
+ 7h	$8.9 \pm 0.8^*$	1.9	2.5 ± 0.9	1.9
+ 7i	$16 \pm 4^*$	3.3	$3.7 \pm 0.1^{***}$	2.8
+ 7j	$6.8 \pm 0.5^*$	1.4	1.8 ± 0.5	1.4
+ 7p	$22 \pm 5^*$	4.6	$8.2 \pm 1.5^*$	6.3

Values are means ($\pm$ SEM) of at least three independent experiments performed in duplicate (* $P < 0.05$, *** $P < 0.001$ versus control).

$K_{\text{v}}11.1$ activators have been introduced as a new potential anti-arrhythmic strategy based on augmentation of the repolarization reserve of cardiomyocytes.³¹ In this context, reference compounds **7a** and **7r** have also been defined as activators.^{18, 21} Compound **7r** had been found to decrease the affinity of $K_{\text{v}}11.1$ blockers dofetilide and droperidol, and to reduce the action potential prolongation by dofetilide in isolated rabbit ventricular cardiomyocytes. In a similar fashion, RPR26024, the first known $K_{\text{v}}11.1$ activator, dose-dependently reversed the action potential-prolonging effects of dofetilide in guinea pig myocytes.¹² We hypothesized that the $K_{\text{v}}11.1$ activators might exert their antiarrhythmic effects through negative allosteric modulation of the binding of $K_{\text{v}}11.1$ blockers to the channel, and verified that this was the case for compound **7r**. Additionally, compound **7a** had been found to relieve APD prolonged by a genetic dysfunction of the $K_{\text{v}}7.1$ channel.¹⁸ Several negative allosteric modulators synthesized in this study displayed higher potencies than **7a** and **7r**, in particular **7f** and **7p**, which

implicates their roles as lead compounds in eventually treating patients with LQT syndromes induced by pharmacological blockade of the $K_v11.1$ channel or due to genetic defects of the potassium channels.




Figure 4. Displacement curves of [³H]dofetilide by dofetilide (control), **7f** and **7p**. Experiments were performed at 25 °C with 20 μg HEK293K_{v11.1} membranes.

Conclusion

In summary, modifications of the three aromatic rings of the basic scaffold from reference compounds **7a** and **7r** lead to a series of compounds comprising of novel negative allosteric modulators of dofetilide binding to the $K_v11.1$ channel. Structure-activity relationships demonstrate that all the three aromatic rings play pivotal roles in determining the allosteric effects of these ligands at the $K_v11.1$ channel. Introducing halogen substituents at the meta-position of phenylcarbonyl ring together with non-substituted pyridine and phenolic rings enhances the negative allosteric effects of these modulators. In the kinetic dissociation assays, these compounds significantly accelerate the dissociation of [³H]dofetilide from the $K_v11.1$ channel. Moreover, several potent modulators shift the displacement curves of prototypical $K_v11.1$ blockers (dofetilide and astemizole) to the right, and thus, diminish their $K_v11.1$ affinity at the channel. This is another indication of their negative allosteric properties, and also implicates their potential antiarrhythmic propensities in reducing acquired LQT syndromes induced by pharmacological blockade. Furthermore, these negative allosteric modulators may also become a new class of medicines for alleviating congenital LQT syndromes linked to both $K_v11.1$ and $K_v7.1$ channels like compound **7a**. Since compounds **7f** and **7p** are more potent than reference compounds **7a** and **7r**, they may serve as lead compounds for further optimization to relieve action potential prolongation through $K_v11.1$ channels or other potassium channels.

Experimental section

Chemistry

All solvents and reagents were purchased from commercial sources and were of analytical grade. Demineralised water is simply referred to as H₂O, as was used in all cases unless stated otherwise (i.e. brine). ¹H and ¹³C NMR spectra were recorded on a Bruker AV 400 liquid spectrometer (¹H NMR, 400 MHz; ¹³C NMR, 100 MHz) at ambient temperature. Chemical shifts are reported in parts per million (ppm), are designated by δ and are downfield to the internal standard tetramethylsilane (TMS) in CDCl₃. Coupling-constants are reported in Hz and are designated as J. Analytical purity of the final compounds was determined by high pressure liquid chromatography (HPLC) with a Phenomenex Gemini 3m C18 110A column (50 x 4.6 mm, 3 μ m), measuring UV absorbance at 254 nm. Sample preparation and HPLC method was - unless stated otherwise - as follows: 0.3-0.8 mg of compound was dissolved in 1 mL of a 1:1:1 mixture of CH₃CN/H₂O/tBuOH and eluted from the column within 15 minutes, with a three component system of H₂O/CH₃CN/1% TFA in H₂O, decreasing polarity of the solvent mixture in time from 80/10/10 to 0/90/10. All compounds showed a single peak at the designated retention time and are at least 95% pure. Liquid chromatography–mass spectrometry (LC-MS) analyses were performed using Thermo Finnigan Surveyor - LCQ Advantage Max LC-MS system and a Gemini C18 Phenomenex column (50 × 4.6 mm, 3 μ m). The sample preparation was the same as for HPLC analysis. The elution method was set up as follows: 1-4 min isocratic system of H₂O/CH₃CN/1% TFA in H₂O, 80:10:10, from the 4th min, a gradient was applied from 80:10:10 to 0:90:10 within 9 min, followed by 1 min of equilibration at 0:90:10 and 1 min at 80:10:10. Thin-layer chromatography (TLC) was routinely performed to monitor the progress of reactions, using aluminium coated Merck silica gel F254 plates. Purification by column chromatography was achieved by use of Grace Davison Davisil silica column material (LC60A 30-200 micron). Solutions were concentrated using a Heidolph laborota W8 2000 efficient rotary evaporation apparatus and by a high vacuum on a Binder APT line Vacuum Drying Oven. Microwave reactions were carried out in a Biotage Initiator using sealed tubes and at a set reaction temperature. The procedure for a series of similar compounds is given as a general procedure for all within that series, annotated by the numbers of the compounds.

Chlorination of bromo-fluoro-substituted-benzoic acids. To 2-bromo-5-fluorobenzoic acid **8p** (500 mg, 2.28 mmol) was added thionyl chloride (207 μ L, 2.85 mmol). The mixture was heated for 1.5 h at 100 °C (an additional

1 mL of SOCl_2 was added after 20 min). The thionyl chloride was evaporated and the product, **2-bromo-5-fluorobenzoyl chloride (2p)**, was used without further purification. 454 mg yield = 84%.

2-Bromo-3-fluorobenzoyl chloride (2o). Methode chlorination of bromo-fluoro-substituted-benzoic acids. Continued without further purification, 436 mg yield = 81%.

3-Amino-5-methoxy pyridine (10f5). 3-Bromo-5-methoxypyridine (**9f5**) (500 mg, 2.66 mmol), ammonium hydroxide (15 mL) and coppersulfate pentahydrate (33 mg, 0.13 mmol) were heated at 140 °C in the microwave in a closed tube for 20 h. The reaction mixture was cooled to room temperature and the crude material separated between ethyl acetate and water. The organic layer was washed with water (3 times) and brine, dried over MgSO_4 , filtered and concentrated *in vacuo* to give 84 mg, yield 25% of the desired product as solids. ^1H NMR (400 MHz, CDCl_3): δ 7.72 (d, J = 5.4 Hz, 2H), 6.51 (t, J = 2.4 Hz, 1H), 3.79 (s, 3H) ppm; HPLC-MS: m/z 125.0

General method for the Friedel Crafts acylation (**3b-l** and **3n-p**).

To a cooled mixture of the substituted benzoyl chloride **2b-l** and **2n-q** (5.71 mmol, 1.0 equiv.) and the (substituted)-anisole **1a-c** (7.14 mmol, 1.25 equiv.) in CH_2Cl_2 (0.2 M) or carbon disulfide (**3b**) was added AlCl_3 (7.14 mmol, 1.25 equiv.) in portions over 20 min under a nitrogen atmosphere. After 24 h at room temperature full conversion was observed with TLC (Pet. ether/EtOAc 19/1) and the reaction mixture was poured into a 3 M aq. HCl solution. The organics were extracted 3 times from the aqueous layer with CH_2Cl_2 , washed with water and brine, dried over MgSO_4 and concentrated *in vacuo*. The obtained crude material was triturated with petroleum ether to obtain the pure products as white solids.

(2-Bromo-4-methoxyphenyl)-phenylmethanone (3b). Started from 3-bromoanisole (**1b**) and benzoyl chloride. Yellow oil 2.20 g after column chromatography (2.5-5% EtOAc/Pet. ether), yield = 75%. ^1H NMR (400 MHz, CDCl_3): δ 7.80 (d, J = 7.2 Hz, 2H), 7.58 (d, J = 7.2 Hz, 1H), 7.45 (t, J = 8.0 Hz, 2H), 7.32 (d, J = 8.8 Hz, 1H), 7.19 (d, J = 2.0 Hz, 1H), 6.92 (dd, J = 8.6, 2.2 Hz, 1H), 3.86 (s, 3H) ppm. NMR in accordance with literature.³²

(3-Bromo-4-methoxyphenyl)-phenylmethanone (3c).³³ Started from 2-bromoanisole (**1c**) and benzoyl chloride. White solids 2.78 g, yield = 64%. ^1H NMR (400 MHz, CDCl_3): δ 8.07 (d, J = 2.0 Hz, 1H), 7.80 (dd, J = 8.4, 2.0 Hz, 1H), 7.77-7.73 (m, 2H), 7.60 (tt, J = 7.2, 1.2 Hz, 1H), 7.49 (t, J = 7.2 Hz, 2H), 6.96 (d, J = 8.8 Hz, 1H), 3.99 (s, 3H), 3.86 (s, 3H) ppm. NMR in accordance with literature data.³⁴

(2-Fluorophenyl)(4-methoxyphenyl)methanone (3d). Started from anisole

(**1a**) and 2-fluorobenzoyl chloride (**2d**). White solids 365 mg, yield = 34%. ^1H NMR (400 MHz, CDCl_3): δ 7.83 (d, J = 8.4 Hz, 2H), 7.52-7.46 (m, 2H), 7.25 (t, J = 7.6 Hz, 1H), 7.14 (t, J = 8.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 2H), 3.86 (s, 3H) ppm. NMR in accordance with literature data.³⁵

(2-Chlorophenyl)(4-methoxyphenyl)methanone (3e). Started from anisole (**1a**) and 2-fluorobenzoyl chloride (**2e**). Pinkish solids 2.43 g, yield = 66%. ^1H NMR (400 MHz, CDCl_3): δ 7.79 (dt, J = 8.8, 2.0 Hz, 2H), 7.47-7.38 (m, 2H), 7.36-7.33 (m, 2H), 6.94 (dt, J = 8.8, 2.0 Hz, 2H), 3.88 (s, 3H) ppm. NMR in accordance with literature data.³⁶

(2-Bromophenyl)(4-methoxyphenyl)methanone (3f). Started from anisole (**1a**) and 2-bromobenzoyl chloride (**2f**). White solids 586 mg, yield = 88%. ^1H NMR (400 MHz, CDCl_3): δ 7.79 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.35-7.31 (m, 2H), 6.94 (d, J = 8.4 Hz, 2H), 3.88 (s, 3H) ppm. NMR in accordance with literature data.³⁶

(2-Iodophenyl)(4-methoxyphenyl)methanone (3g). Started from anisole (**1a**) and 2-iodobenzoyl chloride (**2g**). White solids 422 mg, yield = 66%. ^1H NMR (400 MHz, CDCl_3): δ 7.91 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.44 (t, J = 7.2 Hz, 1H), 7.28 (d, J = 6.8 Hz, 1H), 7.17 (t, J = 7.6 Hz, 1H), 6.94 (d, J = 8.8 Hz, 2H), 3.88 (s, 3H) ppm. NMR in accordance with literature data.³⁷

(3-Fluorophenyl)(4-methoxyphenyl)methanone (3h). Started from anisole (**1a**) and 3-fluorobenzoyl chloride (**2h**). White solids 576 mg, yield = 53%. ^1H NMR (400 MHz, CDCl_3): δ 7.82 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 7.47-7.42 (m, 2H), 7.28-7.24 (m, 1H), 6.97 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H) ppm. NMR in accordance with literature data.³⁸

(3-Chlorophenyl)(4-methoxyphenyl)methanone (3i).³⁹ Started from anisole (**1a**) and 3-chlorobenzoyl chloride (**2i**). Pink solids 2.64 g, yield = 71%. ^1H NMR (400 MHz, CDCl_3): δ 7.80 (dt, J = 8.8, 2.0 Hz, 2H), 7.73 (t, J = 1.6 Hz, 1H), 7.62 (dt, J = 8.0, 1.2 Hz, 1H), 7.53 (dd, J = 8.0, 1.2 Hz, 1H), 7.41 (t, J = 8.0 Hz, 2H), 6.97 (dt, J = 9.2, 1.2 Hz, 2H), 3.89 (s, 3H) ppm.

(3-Bromophenyl)(4-methoxyphenyl)methanone (3j). Started from anisole (**1a**) and 3-bromobenzoyl chloride (**2j**). White solids 649 mg, yield = 49%. ^1H NMR (400 MHz, CDCl_3): δ 7.88 (t, J = 1.6 Hz, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.70-7.65 (m, 2H), 7.37 (t, J = 7.6, 1H), 6.97 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H) ppm. NMR in accordance with literature data.³⁵

(3-Iodophenyl)(4-methoxyphenyl)methanone (3k). Started from anisole (**1a**) and 3-iodobenzoyl chloride (**2k**). White solids 300 mg, yield = 47%. ^1H NMR (400 MHz, CDCl_3): δ 8.08 (s, 1H), 7.90 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 3.90 (s, 3H) ppm. NMR in accordance with literature data.⁴⁰

(4-Methoxyphenyl)(4-methylphenyl)methanone (3l). Started from anisole (**1a**) and 4-methylbenzoyl chloride (**2l**). White solids 2.31 g, yield = 68%. ^1H NMR (400 MHz, CDCl_3): δ 8.81 (dt, $J = 8.8, 2.0$ Hz, 2H), 7.67 (d, $J = 8.0$ Hz, 2H), 7.27 (d, $J = 8.4$ Hz, 2H), 6.96 (dt, $J = 8.8, 2.0$ Hz, 2H), 3.88 (s, 3H) ppm. NMR in accordance with literature data.³⁵

(4-Chlorophenyl)(4-methoxyphenyl)methanone (3n). Started from anisole (**1a**) and 4-chlorobenzoyl chloride (**2n**). White solids 1.02 g, yield = 73%. ^1H NMR (400 MHz, CDCl_3): δ 7.80 (dt, $J = 8.8, 2.0$ Hz, 2H), 7.71 (d, $J = 8.4$ Hz, 2H), 7.45 (d, $J = 8.2$ Hz, 2H), 6.96 (d, $J = 8.4$ Hz, 2H), 3.89 (s, 3H) ppm. NMR in accordance with literature data.³⁵

(2-Bromo-3-fluorophenyl)(4-methoxyphenyl)methanone (3o). Started from anisole (**1a**) and 2-bromo-3-fluorobenzoyl chloride (**2o**). White solids 316 mg, yield = 56%. ^1H NMR (400 MHz, CDCl_3): δ 7.78 (d, $J = 8.8$ Hz, 2H), 7.42-7.36 (m, 1H), 7.23 (td, $J = 8.2, 1.2$ Hz, 1H), 7.12 (dd, $J = 7.6, 0.4$ Hz, 1H), 6.95 (d, $J = 8.8$ Hz, 2H), 3.89 (s, 3H) ppm.

(2-Bromo-5-fluorophenyl)(4-methoxyphenyl)methanone (3p). Started from anisole (**1a**) and 2-bromo-5-fluorobenzoyl chloride (**2p**). White solids 438 mg, yield = 74%. ^1H NMR (400 MHz, CDCl_3): δ 7.79 (d, $J = 8.8$ Hz, 2H), 7.61-7.58 (m, 1H), 7.06 (d, $J = 7.6$ Hz, 2H), 6.95 (d, $J = 9.2$ Hz, 2H), 3.89 (s, 3H) ppm.

General method for demethylation of **3b**, **3d-l** and **3n-p** with aluminum trichloride (**4b**, **4d-l** and **4n-p**).²¹

AlCl_3 (2.5 equiv.) was slowly added to a solution of **3b**, **3d-l** and **3n-p** (1.0 equiv.) in toluene (0.15 M) under a N_2 atmosphere. The mixture was refluxed at 130 °C for 2 h and by TLC (Pet. ether/EtOAc 4/1) full conversion was shown. The cooled mixture was poured into an 3 M HCl (aq.) solution, the organics were extracted with ethyl acetate (3 times), washed with brine, dried over MgSO_4 and concentrated to give the desired 4-(benzoyl)phenols (**4b**, **4d-l** and **4n-p**) as solids.

(2-Bromo-4-hydroxyphenyl)-phenylmethanone (4b). Brownish solids 1.36 g, yield = 65%. ^1H NMR (400 MHz, CDCl_3): δ 7.81 (dd, $J = 8.4, 1.2$ Hz, 2H), 7.60 (t, $J = 7.4$ Hz, 1H), 7.46 (t, $J = 7.6$ Hz, 2H), 7.27 (d, $J = 6.8$ Hz, 1H), 7.16 (d, $J = 2.4$ Hz, 1H), 6.86 (dd, $J = 8.4, 2.4$ Hz, 1H), 6.36 (s br, 1H) ppm.

(2-Fluorophenyl)(4-hydroxyphenyl)methanone (4d).⁴¹ White solids 343 mg, yield = 100%. ^1H NMR (400 MHz, CDCl_3): δ 7.78 (d, $J = 8.4$ Hz, 2H), 7.51-7.48 (m, 2H), 7.26-7.24 (m, 1H), 7.18-7.12 (m, 1H), 6.91 (d, $J = 8.4$ Hz, 2H), 6.58 (s br, 1H) ppm.

(2-Chlorophenyl)(4-hydroxyphenyl)methanone (4e).⁴² White solids 2.17 g, yield = 95%. ^1H NMR (400 MHz, DMSO): δ 10.62 (s, 1H), 7.60-7.56 (m, 3H), 7.53 (td, $J = 8.4, 2.0$ Hz, 1H), 7.47 (td, $J = 8.4, 1.6$ Hz, 1H), 7.42 (dd, $J = 7.6, 1.6$

Hz, 1H), 6.88 (d, $J = 8.8$ Hz, 2H) ppm.

4-(2-Bromophenyl)(4-hydroxyphenyl)methanone (4f).⁴³ Brown oil, yield = quantitative. ¹H NMR (400 MHz, CDCl₃): δ 7.73 (d, $J = 8.4$ Hz, 2H), 7.63 (d, $J = 7.6$ Hz, 1H), 7.40 (t, $J = 7.6$ Hz, 1H), 7.33 (t, $J = 8.8$ Hz, 1H), 6.89 (d, $J = 8.4$ Hz, 2H), 6.69 (s br, 1H) ppm.

4-(4-Hydroxyphenyl)(2-iodophenyl)methanone (4g). White solids 393 mg, yield = 97%. ¹H NMR (400 MHz, CDCl₃): δ 7.90 (d, $J = 8.0$ Hz, 1H), 7.71 (d, $J = 8.8$ Hz, 2H), 7.43 (td, $J = 7.6, 0.8$ Hz, 1H), 7.27 (dd, $J = 7.6, 1.6$ Hz, 1H), 6.90 (d, $J = 8.8$ Hz, 2H) ppm. NMR data in accordance with literature.⁴⁴

4-(3-Fluorophenyl)(4-hydroxyphenyl)methanone (4h). White solids 172 mg, yield = 73%. ¹H NMR (400 MHz, CDCl₃): δ 7.77 (d, $J = 8.4$ Hz, 2H), 7.53 (d, $J = 8.0$ Hz, 1H), 7.48-7.43 (m, 2H), 7.30-7.18 (m, 1H), 6.95 (d, $J = 8.0, 0.8$ Hz, 2H) ppm. NMR data in accordance with literature.⁴⁵

4-(3-Chlorophenyl)(4-hydroxyphenyl)methanone (4i). Off white solids 2.35 g, yield = 95%. ¹H NMR (400 MHz, DMSO): δ 10.54 (s, 1H), 7.71-7.63 (m, 4H), 7.60-7.53 (m, 2H), 6.90 (dt, $J = 8.8, 2.0$ Hz, 2H) ppm. NMR data in accordance with literature.⁴⁶

4-(3-Bromophenyl)(4-hydroxyphenyl)methanone (4j). White solids 168 mg, yield = 88%. ¹H NMR (400 MHz, CDCl₃): δ 7.88 (t, $J = 1.6$ Hz, 1H), 7.77 (d, $J = 8.8$ Hz, 2H), 7.70 (dt, $J = 8.0, 1.2$ Hz, 1H), 7.66 (d, $J = 7.6$ Hz, 1H), 7.36 (t, $J = 8.0$ Hz, 1H), 6.93 (d, $J = 8.4$ Hz, 2H), 6.92 (s br, 1H) ppm. NMR data in accordance with literature.⁴⁷

4-(4-Hydroxyphenyl)(3-iodophenyl)methanone (4k). Brown solids 209 mg, yield = 73%. ¹H NMR (400 MHz, CDCl₃): δ 8.08 (s, 1H), 7.90 (d, $J = 8.0$ Hz, 1H), 7.77 (d, $J = 8.4$ Hz, 2H), 7.70 (d, $J = 7.6$ Hz, 1H), 7.22 (t, $J = 8.0$ Hz, 1H), 6.93 (d, $J = 8.8$ Hz, 2H), 5.74 (s br, 1H) ppm. NMR data in accordance with literature.⁴⁶

4-(4-Hydroxyphenyl)(4-methylphenyl)methanone (4l).⁴⁸ Brown solids 2.03 g, yield = 94%. ¹H NMR (400 MHz, DMSO): δ 10.39 (s, 1H), 7.64 (d, $J = 8.4$ Hz, 2H), 7.57 (d, $J = 8.0$ Hz, 2H), 7.33 (d, $J = 8.0$ Hz, 2H), 7.88 (d, $J = 8.8$ Hz, 2H), 2.39 (s, 3H) ppm.

4-(4-Chlorophenyl)(4-hydroxyphenyl)methanone (4n). Off white solids 821 mg, yield = 85%. ¹H NMR (400 MHz, CDCl₃): δ 7.76 (d, $J = 8.8$ Hz, 2H), 7.71 (d, $J = 8.8$ Hz, 2H), 7.46 (d, $J = 8.4$ Hz, 2H), 6.93 (d, $J = 8.8$ Hz, 2H), 6.15 (s br, 1H). NMR data in accordance with literature.⁴⁹

(2-Bromo-3-fluorophenyl)(4-hydroxyphenyl)methanone (4o). Off white solids 301 mg, yield = 100 %. ¹H NMR (400 MHz, CDCl₃): δ 8.32 (s br, 1H), 7.72 (dd, $J = 6.8, 2.0$ Hz, 2H), 7.41-7.35 (m, 1H), 7.22 (td, $J = 8.4, 2.0$ Hz, 1H), 7.11 (dd, $J = 7.6, 0.8$ Hz, 1H), 6.92 (dd, $J = 7.2, 1.6$ Hz, 2H) ppm.

(2-Bromo-5-fluorophenyl)(4-hydroxyphenyl)methanone (4p). White solids 236 mg, yield = 56%. ^1H NMR (400 MHz, CDCl_3): δ 8.49 (s br, 1H), 7.72 (dt, $J = 8.8, 2.4$ Hz, 2H), 7.60-7.57 (m, 1H), 7.09-7.04 (m, 2H), 6.93 (dd, $J = 8.8, 2.4$ Hz, 2H) ppm.

(3-Bromo-4-hydroxyphenyl)-phenylmethanone (4c). At -78°C **3c** (873 mg, 3.00 mmol, 1.0 equiv.) was dissolved in 20 mL of CH_2Cl_2 and a solution of BBr_3 in CH_2Cl_2 (1 M) (15 mL, 15 mmol, 5 equiv.) was added under a N_2 atmosphere. The mixture was stirred at room temperature and after 24 h cooled again to -78°C and quenched with water. The organics were extracted with CH_2Cl_2 (4 times) from the aqueous layer, dried over MgSO_4 and concentrated. The pure **4c** (584 mg of a yellowish solid yield = 70%) was obtained by column chromatography eluting with a gradient of CH_2Cl_2 to 2% MeOH in CH_2Cl_2 . ^1H NMR (400 MHz, CDCl_3): δ 8.03 (d, $J = 2.0$ Hz, 1H), 7.77-7.18 (m, 3H), 7.59 (tt, $J = 7.6, 1.6$ Hz, 1H), 7.50 (t, $J = 7.6$ Hz, 2H), 7.10 (d, $J = 8.4$ Hz, 1H), 6.00 (s, 1H) ppm.

General method for *O*-alkylation yielding compounds **5a-q**.

To a solution of **5a-q** (1.0 eq.) in DMF (0.2 M) was added K_2CO_3 (2.0 equiv.) and 2-methyl bromoacetate (2.0 equiv.). The mixture was stirred at 65°C for 24 h, after which it was cooled to room temperature and the mixture was separated between ethyl acetate and water. The organic layer was washed with water (3 times), brine, dried over MgSO_4 , and concentrated. This gave the desired *O*-alkylated products (**5a-q**) as one spot on TLC (1 EtOAc/4 Pet. ether) and used as crude material in the next reaction or purified as specified in the individual examples.

Methyl 2-(4-benzoylphenoxy)acetate (5a).⁵⁰ Recrystallized from EtOAc/Pet. ether. White solids 1.52 g, yield = 56%. ^1H NMR (400 MHz, CDCl_3): δ 7.83 (d, $J = 8.8$ Hz, 2H), 7.76 (d, $J = 8.0$ Hz, 2H), 7.57 (t, $J = 8.0$ Hz, 1H), 7.48 (t, $J = 8.0$ Hz, 2H), 6.97 (d, $J = 8.8$ Hz, 2H), 4.73 (s, 2H), 3.83 (s, 3H) ppm.

Methyl 2-(4-benzoyl-3-bromophenoxy)acetate (5b). Used as crude in the next reaction, yield = quantitative. ^1H NMR (400 MHz, CDCl_3): δ 7.79 (d, $J = 7.6$ Hz, 2H), 7.59 (t, $J = 7.2$ Hz, 1H), 7.46 (t, $J = 7.6$ Hz, 2H), 7.32 (d, $J = 8.4$ Hz, 1H), 7.20 (d, $J = 1.6$ Hz, 1H), 6.93 (dd, $J = 8.4, 1.6$ Hz, 1H), 4.69 (s, 2H), 3.83 (s, 3H) ppm.

Methyl 2-(4-benzoyl-2-bromophenoxy)acetate (5c). Started from **4c** (2.11 mmol) and this gave 606 mg of the product as a colorless oil after column chromatography using the gradient 1/1 Pet. ether/ CH_2Cl_2 to CH_2Cl_2 , yield = 82%. ^1H NMR (400 MHz, CDCl_3): δ 8.08 (d, $J = 2.0$ Hz, 1H), 7.78-7.74 (m, 3H), 7.60 (t, $J = 7.6$ Hz, 1H), 7.49 (t, $J = 7.6$ Hz, 2H), 6.83 (d, $J = 7.6$ Hz, 1H), 4.82 (s, 2H), 3.83 (s, 3H) ppm.

Methyl 2-(4-(2-fluorobenzoyl)phenoxy)acetate (5d). Used as crude in the next reaction, yield = quantitative. ^1H NMR (400 MHz, CDCl_3): δ 7.84 (d, J = 8.4 Hz, 2H), 7.54-7.48 (m, 2H), 7.28-7.24 (m, 1H), 7.16 (t, J = 9.2 Hz, 1H), 6.96 (d, J = 8.8 Hz, 2H), 4.72 (s, 2H), 3.82 (s, 3H) ppm.

Methyl 2-(4-(2-chlorobenzoyl)phenoxy)acetate (5e). Colorless oil 2.36 g, yield = 83%. ^1H NMR (400 MHz, DMSO): δ 7.76 (dt, J = 8.8, 1.6 Hz, 2H), 7.61-7.54 (m, 2H), 7.51-7.45 (m, 2H), 7.09 (dt, J = 8.8, 2.0 Hz, 2H), 4.94 (s, 2H), 3.70 (s, 3H) ppm.

Methyl 2-(4-(2-bromobenzoyl)phenoxy)acetate (5f). Colorless oil after column chromatography using the gradient 4/1 Pet. ether/EtOAc 341 mg, yield = 75%. ^1H NMR (400 MHz, CDCl_3): δ 7.79 (d, J = 8.8 Hz, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.41 (t, J = 7.2 Hz, 1H), 7.36-7.30 (m, 2H), 6.94 (d, J = 8.8 Hz, 2H), 4.71 (s, 2H), 3.82 (s, 3H) ppm.

Methyl 2-(4-(2-iodobenzoyl)phenoxy)acetate (5g). Used as crude material in the next reaction, brown oil 444 mg, yield = 93%. ^1H NMR (400 MHz, CDCl_3): δ 7.91 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.44 (t, J = 7.6 Hz, 1H), 7.27 (dd, J = 7.6, 1.2 Hz, 1H), 7.17 (td, J = 7.6, 1.6 Hz, 1H), 6.95 (d, J = 9.2 Hz, 2H), 4.73 (s, 2H), 3.81 (s, 3H) ppm.

Methyl 2-(4-(3-fluorobenzoyl)phenoxy)acetate (5h). Used as crude material in the next reaction, brown oil 244 mg, yield = quantitative. ^1H NMR (400 MHz, CDCl_3): δ 7.82 (dd, J = 8.8, 2.8 Hz, 2H), 7.52 (dd, J = 7.6, 0.8 Hz, 1H), 7.48-7.44 (m, 2H), 7.28 (d, J = 7.2 Hz, 1H), 6.98 (dd, J = 8.8, 2.4 Hz, 2H), 4.72 (s, 2H), 3.82 (s, 3H) ppm.

Methyl 2-(4-(3-chlorobenzoyl)phenoxy)acetate (5i). Washed crude mixture with Pet. ether, off white solids 2.86 g, yield = 93%. ^1H NMR (400 MHz, DMSO): δ 7.78-7.70 (m, 3H), 7.68 (t, J = 1.6 Hz, 1H), 7.62 (dt, J = 8.0, 1.6 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.11 (d, J = 8.8 Hz, 2H), 4.95 (s, 2H), 3.72 (s, 3H) ppm.

Methyl 2-(4-(3-bromobenzoyl)phenoxy)acetate (5j). Washed crude mixture with Pet. ether, off white solids 253 mg, yield = 99%. ^1H NMR (400 MHz, CDCl_3): δ 7.89 (t, J = 2.0 Hz, 1H), 7.81 (d, J = 8.8 Hz, 2H), 7.72-7.66 (m, 2H), 7.36 (t, J = 7.6 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 4.74 (s, 2H), 3.84 (s, 3H) ppm.

Methyl 2-(4-(3-iodobenzoyl)phenoxy)acetate (5k). Washed crude mixture with Pet. ether, off white solids 243 mg, yield = 99%. ^1H NMR (400 MHz, CDCl_3): δ 8.08 (t, J = 1.6 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.81 (dt, J = 8.2, 2.0 Hz, 2H), 7.70 (dt, J = 8.0, 1.2 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 4.73 (s, 2H), 3.83 (s, 3H) ppm.

Methyl 2-(4-(4-methylbenzoyl)phenoxy)acetate (5l). Washed crude mixture with Pet. ether, off white solids 2.71 g, yield = 99%. ^1H NMR (400 MHz, CDCl_3): δ 7.80 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz,

2H), 6.96 (d, $J = 8.4$ Hz, 2H), 4.72 (s, 2H), 3.83 (s, 3H), 2.44 (s, 3H) ppm.

Methyl 2-(4-(4-fluorobenzoyl)phenoxy)acetate (5m). Started from the commercially available **4m**. Washed crude mixture with Pet. ether, white solids 2.53 g, yield = 95%. ^1H NMR (400 MHz, DMSO): δ 7.80-7.76 (m, 2H), 7.73 (dt, $J = 8.8, 2.0$ Hz, 2H), 7.38 (tt, $J = 9.2, 2.4$ Hz, 2H), 7.09 (dt, $J = 8.8, 2.0$ Hz, 2H), 4.95 (s, 2H), 3.72 (s, 3H) ppm.

Methyl 2-(4-(4-chlorobenzoyl)phenoxy)acetate (5n). Used as crude material in the next reaction, yield was quantitative. ^1H NMR (400 MHz, CDCl_3): δ 7.80 (d, $J = 8.8$ Hz, 2H), 7.71 (d, $J = 8.4$ Hz, 2H), 7.46 (d, $J = 8.4$ Hz, 2H), 6.98 (d, $J = 8.8$ Hz, 2H), 4.73 (s, 2H), 3.83 (s, 3H) ppm.

Methyl 2-(4-(2-bromo-3-fluorobenzoyl)phenoxy)acetate (5o). Off white solids 275 mg, yield = 73%. ^1H NMR (400 MHz, CDCl_3): δ 7.77 (d, $J = 8.8$ Hz, 2H), 7.43-7.38 (m, 1H), 7.24 (td, $J = 8.4, 1.2$ Hz, 1H), 7.11 (d, $J = 7.6$ Hz, 1H), 6.95 (d, $J = 8.8$ Hz, 2H), 4.73 (s, 2H), 3.79 (s, 3H) ppm.

Methyl 2-(4-(2-bromo-5-fluorobenzoyl)phenoxy)acetate (5p). Used as crude material in the next reaction, yield = 98%. ^1H NMR (400 MHz, CDCl_3): δ 7.78 (d, $J = 8.4$ Hz, 2H), 7.62-7.57 (m, 1H), 7.10-7.04 (m, 2H), 6.96 (d, $J = 8.4$ Hz, 2H), 4.73 (s, 2H), 3.80 (s, 3H) ppm.

Methyl 2-((9-oxo-9H-fluoren-3-yl)oxy)acetate (5q). Started from **4b** (2.11 mmol) and this gave 309 mg as yellow solids after column chromatography using CH_2Cl_2 as an eluent, yield = 92%. ^1H NMR (400 MHz, CDCl_3): δ 7.64-7.60 (m, 2H), 7.48-7.45 (m, 2H), 7.33-7.27 (m, 1H), 7.07 (d, $J = 2.4$ Hz, 1H), 6.71 (dd, $J = 8.0, 2.0$ Hz, 1H), 4.74 (s, 2H), 3.84 (s, 3H) ppm.

General saponification procedure to obtain acids 6a-q.

To a solution of **5a-i** (1.0 eq.) in a mixture of equal amounts of THF and methanol (0.5 M solution) was added an aqueous 1 M solution of LiOH (5.0 eq.). After 1 hour at 100 °C the saponification of the esters **6a-q** was completed shown by TLC (EtOAc/Pet. ether 1/3). While the mixture was cooled on ice, the pH was adjusted to pH = 1 using a 2 M HCl solution (aq.). The resulting precipitate was collected by filtration, washed with water, Pet. ether and co-evaporated with acetone to dryness.

2-(4-Benzoylphenoxy)acetic acid (6a).⁵¹ White solids 1.37 g, yield = 95%. ^1H NMR (400 MHz, CDCl_3 + drop of DMSO): δ 9.50 (s br, 1H), 7.82 (d, $J = 8.4$ Hz, 2H), 7.75 (d, $J = 7.6$ Hz, 2H), 7.58 (t, $J = 7.6$ Hz, 1H), 7.47 (t, $J = 7.6$ Hz, 2H), 7.00 (d, $J = 8.8$ Hz, 2H), 4.69 (s, 2H) ppm.

2-(4-Benzoyl-2-bromophenoxy)acetic acid (6b). White solids 548 mg, yield = 95%. ^1H NMR (400 MHz, CDCl_3): δ 8.06 (d, $J = 2.0$ Hz, 1H), 7.77-7.34 (m, 3H), 6.60 (t, $J = 7.6$ Hz, 1H), 7.50 (t, $J = 8.0$ Hz, 2H), 6.89 (d, $J = 8.4$ Hz,

1H), 4.78 (s, 2H) ppm.

2-(4-Benzoyl-3-bromophenoxy)acetic acid (6c). Brown solids 1.28 g, yield = 78%. ¹H NMR (400 MHz, CDCl₃): δ 8.88 (s, br, 1H), 7.80 (d, *J* = 8.0 Hz, 2H), 7.63-7.58 (m, 1H), 7.50-7.44 (m, 2H), 7.34 (d, *J* = 8.4 Hz, 1H), 7.23 (d, *J* = 2.4 Hz, 1H), 6.96 (dd, *J* = 8.8, 2.4 Hz, 1H), 4.76 (s, 2H) ppm.

2-(4-(2-Fluorobenzoyl)phenoxy)acetic acid (6d). Off white solids 312 mg, yield = 67%. ¹H NMR (400 MHz, DMSO): δ 13.12 (s br, 1H), 7.73 (d, *J* = 8.4 Hz, 2H), 7.67-7.61 (m, 1H), 7.53 (td, *J* = 7.8, 1.2 Hz, 1H), 7.40-7.34 (m, 2H), 7.07 (d, *J* = 8.8 Hz, 2H), 4.82 (s, 2H) ppm.

2-(4-(2-Chlorobenzoyl)phenoxy)acetic acid (6e). White solids 1.77 g, yield = 79%. ¹H NMR (400 MHz, DMSO): δ 7.67 (dt, *J* = 8.8, 2.0 Hz, 2H), 7.62-7.53 (m, 2H), 7.51-7.43 (m, 2H), 7.05 (d, *J* = 9.2 Hz, 2H), 4.81 (s, 2H) ppm.

2-(4-(2-Bromobenzoyl)phenoxy)acetic acid (6f). Off white solids 8.60 g, yield = 86%. ¹H NMR (400 MHz, CDCl₃): δ 9.17 (s, br, 1H), 7.80 (d, *J* = 8.4 Hz, 2H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.43-7.30 (m, 3H), 6.95 (d, *J* = 8.8 Hz, 2H), 4.75 (s, 2H) ppm.

2-(4-(2-Iodobenzoyl)phenoxy)acetic acid (6g). White solids 302 mg, yield = 71%. ¹H NMR (400 MHz, DMSO): δ 7.96 (d, *J* = 7.6 Hz, 1H), 7.64 (d, *J* = 8.8 Hz, 2H), 7.54 (t, *J* = 7.6 Hz, 1H), 7.35 (d, *J* = 7.6 Hz, 1H), 7.28 (t, *J* = 7.6 Hz, 1H), 7.06 (d, *J* = 8.8 Hz, 2H), 4.81 (s, 2H) ppm.

2-(4-(3-Fluorobenzoyl)phenoxy)acetic acid (6h). Brown solids 94 mg, yield = 45%. ¹H NMR (400 MHz, DMSO): δ 7.76 (d, *J* = 8.8 Hz, 2H), 7.63-7.56 (m, 1H), 7.52-7.46 (m, 3H), 7.08 (d, *J* = 9.2 Hz, 2H), 4.82 (s, 2H) ppm.

2-(4-(3-Chlorobenzoyl)phenoxy)acetic acid (6i). White solids 2.65 g, yield = 97%. ¹H NMR (400 MHz, DMSO): δ 7.75-7.69 (m, 3H), 7.67 (s, 1H), 7.61 (t, *J* = 7.6 Hz, 1H), 7.57 (t, *J* = 7.6 Hz, 1H), 7.04 (d, *J* = 8.8 Hz, 2H), 4.71 (s, 2H) ppm.

2-(4-(3-Bromobenzoyl)phenoxy)acetic acid (6j). White solids 146 mg, yield = 61%. ¹H NMR (400 MHz, DMSO): δ 7.86 (d, *J* = 8.0 Hz, 1H), 7.81 (s, 1H), 7.74 (d, *J* = 8.0 Hz, 2H), 7.67 (d, *J* = 7.2 Hz, 1H), 7.51 (t, *J* = 8.0 Hz, 1H), 7.08 (*J* = 8.0 Hz, 2H), 4.81 (s, 2H) ppm.

2-(4-(3-Iodobenzoyl)phenoxy)acetic acid (6k). White solids 118 mg, yield = 51%. ¹H NMR (400 MHz, DMSO): δ 8.01 (d, *J* = 7.6 Hz, 1H), 7.97 (s, 1H), 7.73 (d, *J* = 8.4 Hz, 2H), 7.67 (d, *J* = 7.6 Hz, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.08 (d, *J* = 8.8 Hz, 2H), 4.82 (s, 2H) ppm.

2-(4-(4-Methylbenzoyl)phenoxy)acetic acid (6l). Off white solids 2.16 g, yield = 81%. ¹H NMR (400 MHz, DMSO): δ 7.70 (d, *J* = 8.8 Hz, 2H), 7.60 (d, *J* = 8.0 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.04 (d, *J* = 9.2 Hz, 2H), 4.76 (s, 2H), 2.40 (s, 3H) ppm. NMR data in accordance with literature.⁵²

2-(4-(4-Fluorobenzoyl)phenoxy)acetic acid (6m). White solids after recryst-

tallization from MeOH 1.55 g, yield = 64%. ^1H NMR (400 MHz, DMSO): δ 13.20 (s br, 1H), 7.80-7.75 (m, 2H), 7.73 (d, J = 8.8 Hz, 2H), 7.37 (t, J = 8.8 Hz, 2H), 7.07 (d, J = 8.8 Hz, 2H), 4.81 (s, 2H) ppm.

2-(4-(4-Chlorobenzoyl)phenoxy)acetic acid (6n).⁵³ White solids 730 mg, yield 71%. ^1H NMR (400 MHz, DMSO): δ 7.73-7.70 (m, 4H), 7.61 (d, J = 7.6 Hz, 2H), 7.05 (d, J = 8.0 Hz, 2H), 4.74 (s, 2H) ppm.

2-(4-(2-Bromo-3-fluorobenzoyl)phenoxy)acetic acid (6o). White solids 225 mg, yield = 85%. ^1H NMR (400 MHz, CDCl_3): δ 8.89 (s br, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.43-7.37 (m, 1H), 7.25 (td, J = 8.4, 1.6 Hz, 1H), 7.12 (d, J = 7.2 Hz, 1H), 6.97 (d, J = 8.8 Hz, 2H), 4.77 (s, 2H) ppm.

2-(4-(2-Bromo-5-fluorobenzoyl)phenoxy)acetic acid (6p). White solid 231 mg, yield = 83%. ^1H NMR (400 MHz, CDCl_3): δ 10.07 (s, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.61-7.56 (m, 1H), 7.10-7.03 (m, 2H), 6.96 (d, J = 8.8 Hz, 2H), 4.75 (s, 2H) ppm.

2-((9-Oxo-9H-fluoren-3-yl)oxy)acetic acid (6q). Yellow solids 255 mg, yield = 87%. ^1H NMR (400 MHz, DMSO): δ 13.20 (br s, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.62-7.54 (m, 3H), 7.46 (s, 1H), 7.38 (t, J = 7.6 Hz, 1H), 6.84 (d, J = 6.8 Hz, 1H), 4.87 (s, 2H) ppm.

General peptide coupling method (7a-r and 7f1-f11).

To a solution of **6a-r** (1.0 equiv.) and Et_3N (1.5 equiv.) in DMF (0.125 M) was added 3-aminopyridine (1.1 equiv.) and HATU (1.1 equiv.) or EDCI*HCl (**7e** and **7l**). The mixture was stirred at room temperature for 20 h. The mixture was separated between ethyl acetate and water. The organic layer was washed with water twice, brine, dried over MgSO_4 and concentrated. Column chromatography using mixtures of 5% methanol/dichloromethane or EtOAc:Pet.ether 2:1 gave the pure desired products.

2-(4-Benzoylphenoxy)-N-(pyridin-3-yl)acetamide (7a).¹⁸ White solid, 211 mg, yield = 69%. ^1H NMR (400 MHz, CDCl_3): δ 8.70 (s br, 1H), 8.44 (s br, 1H), 8.40 (s br, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 7.6 Hz, 2H), 7.60 (t, J = 7.6 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.34 (d, J = 7.2 Hz, 1H), 7.09 (d, J = 8.8 Hz, 2H), 4.74 (s, 2H) ppm; ^{13}C NMR (101 MHz, CDCl_3): δ 195.3, 166.4, 160.2, 137.4, 132.4, 132.2, 131.2, 129.5, 128.1, 127.8, 114.1, 67.2 ppm.; HPLC t_{R} = 7.28 min. purity 100%; ESI-MS: 333.13 $[\text{M}+\text{H}]^+$.

2-(4-Benzoyl-3-bromophenoxy)-N-(pyridin-3-yl)acetamide (7b). White solid, 158 mg, yield = 51%. ^1H NMR (400 MHz, CDCl_3): δ 8.71 (s, 1H), 8.43 (d, J = 4.8 Hz, 2H), 8.24 (d, J = 8.0 Hz, 1H), 7.80 (d, J = 7.6 Hz, 2H), 7.61 (t, J = 7.6 Hz, 1H), 7.47 (t, J = 7.8 Hz, 2H), 7.39-7.31 (m, 3H), 7.03 (d, J = 8.4 Hz, 1H), 4.71 (s, 2H) ppm; HPLC t_{R} = 7.15 min. purity 98%; ESI-MS: 411.13 $[\text{M}+\text{H}]^+$.

2-(4-Benzoyl-2-bromophenoxy)-*N*-(pyridin-3-yl)acetamide (7c). White solid, 293 mg, yield = 71%. ¹H NMR (400 MHz, CDCl₃): δ 8.80 (s, 1H), 8.74 (d, *J* = 2.4 Hz, 1H), 8.44 (d, *J* = 4.8 Hz, 1H), 8.27-8.23 (m, 1H), 8.15 (d, *J* = 1.6 Hz, 1H), 7.83 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.80-7.74 (m, 2H), 7.63 (t, *J* = 7.6 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.35 (dd, *J* = 8.4, 4.8 Hz, 1H), 7.00 (d, *J* = 8.8 Hz, 1H), 4.78 (s, 2H) ppm; HPLC *t*_R = 7.29 min. purity 100%; ESI-MS: 411.07 [M+H]⁺.

2-[4-(2-Fluorobenzoyl)phenoxy]-*N*-(pyridin-3-yl)acetamide (7d). White solid, 150 mg, yield = 78%. ¹H NMR (400 MHz, CDCl₃): δ 8.71 (s, 2H), 8.39 (d, *J* = 3.6 Hz, 1H), 8.20 (d, *J* = 8.0 Hz, 1H), 7.84 (d, *J* = 8.4 Hz, 2H), 7.55-7.49 (m, 2H), 7.31-7.24 (m, 2H), 7.15 (t, *J* = 8.4 Hz, 1H), 7.02 (d, *J* = 9.2 Hz, 2H), 4.70 (s, 2H) ppm; HPLC *t*_R = 6.67 min. purity 98%; ESI-MS: 351.13 [M+H]⁺.

2-[4-(2-Chlorobenzoyl)phenoxy]-*N*-(pyridin-3-yl)acetamide (7e). Used EDCI*HCl instead of HATU. White solid, 72 mg, yield = 20%. ¹H NMR (400 MHz, CDCl₃): δ 8.70-8.60 (m, 2H), 8.39 (d, *J* = 4.4 Hz, 1H), 8.19 (d, *J* = 8.0 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 2H), 7.45-7.28 (m, 5H), 7.02 (d, *J* = 8.4 Hz, 2H), 4.71 (s, 2H) ppm; HPLC *t*_R = 7.04 min. purity 100%; ESI-MS: 367.13 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-*N*-(pyridin-3-yl)acetamide (7f). White solid, 9 mg, yield = 23%. ¹H NMR (400 MHz, CDCl₃): δ 8.68 (d, *J* = 2.0 Hz, 1H), 8.42 (d, *J* = 4.4 Hz, 1H), 8.36 (s, 1H), 8.22 (dt, *J* = 8.4, 0.8 Hz, 1H), 7.85 (d, *J* = 8.8 Hz, 2H), 7.65 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.43 (td, *J* = 7.4, 1.2 Hz, 1H), 7.38-7.31 (m, 3H), 7.06 (d, *J* = 8.8 Hz, 2H), 4.72 (s, 2H) ppm; HPLC *t*_R = 7.09 min. purity 98%; ESI-MS: 411.07 [M+H]⁺.

2-[4-(2-Iodobenzoyl)phenoxy]-*N*-(pyridin-3-yl)acetamide (7g). White solid, 113 mg, yield = 63%. ¹H NMR (400 MHz, CDCl₃): δ 8.68 (s, 1H), 8.43 (d, *J* = 4.4 Hz, 1H), 8.34 (s, 1H), 8.23 (d, *J* = 8.4 Hz, 1H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.85 (d, *J* = 8.4 Hz, 2H), 7.46 (t, *J* = 7.6 Hz, 1H), 7.33 (dd, *J* = 8.4 Hz, 4.8 Hz, 1H), 7.29 (d, *J* = 7.6 Hz, 1H), 7.20 (td, *J* = 7.6 Hz, 1.2 Hz, 1H), 7.07 (d, *J* = 8.8 Hz, 2H), 4.73 (s, 2H) ppm; HPLC *t*_R = 7.19 min. purity 100%; ESI-MS: 459.00 [M+H]⁺.

2-[4-(3-Fluorobenzoyl)phenoxy]-*N*-(pyridin-3-yl)acetamide (7h). White solid, 80 mg, yield = 67%. ¹H NMR (400 MHz, CDCl₃): δ 8.83 (s, 1H), 8.73 (d, *J* = 2.4 Hz, 1H), 8.39 (d, *J* = 4.0 Hz, 1H), 8.21 (d, *J* = 8.8 Hz, 1H), 7.82 (d, *J* = 8.8 Hz, 2H), 7.52-7.42 (m, 3H), 7.32-7.27 (m, 2H), 7.04 (d, *J* = 8.8 Hz, 2H), 4.73 (s, 2H) ppm; HPLC *t*_R = 6.88 min. purity 100%; ESI-MS: 351.13 [M+H]⁺.

2-[4-(3-Chlorobenzoyl)phenoxy]-*N*-(pyridin-3-yl)acetamide (7i). White solid, 319 mg, yield = 87%. ¹H NMR (400 MHz, CDCl₃): δ 8.72 (d, *J* = 2.0 Hz, 1H), 8.44-8.40 (m, 2H), 8.27 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.88 (d, *J* = 8.8 Hz, 2H), 7.74 (t, *J* = 1.6 Hz, 1H), 7.63 (dt, *J* = 7.6, 1.6 Hz, 1H), 7.58-7.55 (m, 1H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.36 (dd, *J* = 8.4, 4.8 Hz, 1H), 7.11 (d, *J* = 8.8 Hz, 2H), 4.75 (s,

2H) ppm; HPLC t_R = 7.33 min. purity 100%; ESI-MS: 367.07 [M+H]⁺.

2-[4-(3-Bromobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7j). White solid, 63 mg, yield = 25%. ¹H NMR (400 MHz, DMSO): δ 10.42 (d, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.30 (d, J = 4.0 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.81 (s, 1H), 7.78 (d, J = 8.8 Hz, 2H), 7.67 (d, J = 8.0 Hz, 1H), 7.51 (t, J = 7.6 Hz, 1H), 7.39-7.36 (m, 1H), 7.18 (d, J = 8.8 Hz, 2H), 4.90 (s, 2H) ppm; HPLC t_R = 7.42 min. purity 98%; ESI-MS: 411.13 [M+H]⁺.

2-[4-(3-Iodobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7k). White solid, 91 mg, yield = 71%. ¹H NMR (400 MHz, DMSO): δ 8.79 (d, J = 2.4 Hz, 1H), 8.30 (dd, J = 4.8, 1.2 Hz, 1H), 8.07 (dt, J = 8.0, 1.6 Hz, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.98 (t, J = 1.2 Hz, 1H), 7.77 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 7.6 Hz, 1H), 7.39-7.33 (m, 2H), 7.17 (d, J = 8.8 Hz, 2H), 4.89 (s, 2H) ppm; HPLC t_R = 7.50 min. purity 98%; ESI-MS: 459.07 [M+H]⁺.

2-[4-(4-Methylbenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7l). Used EDCI*HCl instead of HATU. White solid, 81 mg, yield = 26%. ¹H NMR (400 MHz, CDCl₃): δ 8.69 (d, J = 1.6 Hz, 1H), 8.45-8.38 (m, 2H), 8.23 (dd, J = 7.2, 1.2 Hz, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.68 (d, J = 8.0 Hz, 2H), 7.33 (dd, J = 8.4, 4.8 Hz, 1H), 7.28 (d, J = 7.2 Hz, 2H), 7.07 (d, J = 8.8 Hz, 2H), 4.73 (s, 2H), 2.45 (s, 3H) ppm; HPLC t_R = 7.09 min. purity 98%; ESI-MS: 347.13 [M+H]⁺.

2-(4-(4-Fluorobenzoyl)phenoxy)-N-(pyridin-3-yl)acetamide (7m). White solid, 187 mg, yield = 53%. ¹H NMR (400 MHz, CDCl₃): δ 8.72 (d, J = 2.4 Hz, 1H), 8.44-8.40 (m, 2H), 8.30-8.23 (m, 1H), 7.85 (d, J = 8.8 Hz, 2H), 7.83-7.77 (m, 2H), 7.35 (dd, J = 8.4, 4.8 Hz, 1H), 7.17 (t, J = 8.8 Hz, 2H), 7.09 (d, J = 8.8 Hz, 2H), 4.74 (s, 2H) ppm; HPLC t_R = 6.89 min. purity 99%; ESI-MS: 351.13 [M+H]⁺.

2-[4-(4-Chlorobenzoyl)phenoxy]-N-(pyridin-3-yl)acetamide (7n).¹⁸ White solid, 903 mg, yield = 98%. ¹H NMR (400 MHz, DMSO): δ 10.41 (s, 1H), 8.79 (d, J = 2.4 Hz, 1H), 8.30 (dd, J = 4.4, 1.2 Hz, 1H), 8.07 (dt, J = 8.0, 1.6 Hz, 1H), 7.77 (d, J = 8.8 Hz, 2H), 7.72 (dd, J = 8.8, 2.0 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 7.38 (dd, J = 8.4, 4.8 Hz, 1H), 7.17 (d, J = 8.8 Hz, 2H), 4.89 (s, 2H) ppm; HPLC t_R = 7.27 min. purity 100%; ESI-MS: 367.13 [M+H]⁺.

2-[4-(2-Bromo-3-fluorobenzoyl)phenoxy]-N-(5-methoxypyridin-3-yl)acetamide (7o). White solid, 69 mg, yield = 25%. ¹H NMR (400 MHz, CDCl₃): δ 8.68 (d, J = 2.0 Hz, 1H), 8.42 (d, J = 4.4 Hz, 1H), 8.37 (s, 1H), 8.22 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.44-7.39 (m, 1H), 7.33 (dd, J = 8.2, 4.8 Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H), 7.13 (d, J = 7.6 Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 4.72 (s, 2H) ppm; HPLC t_R = 7.25 min. purity 98%; ESI-MS: 429.07 [M+H]⁺.

2-[4-(2-Bromo-5-fluorobenzoyl)phenoxy]-N-(5-methoxypyridin-3-yl)acetamide (7p). White solid, 108 mg, yield = 39%. ¹H NMR (400 MHz, CDCl₃):

δ 8.67 (s, 1H), 8.43 (d, J = 4.4 Hz, 1H), 8.28 (s, 1H), 8.21 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.61 (dd, J = 8.4, 4.8 Hz, 1H), 7.33 (dd, J = 8.0, 4.8 Hz, 1H), 7.14-7.03 (m, 4H), 4.73 (s, 2H) ppm; HPLC t_R = 7.22 min. purity 100%; ESI-MS: 429.07 [M+H]⁺.

2-[(9-Oxo-9H-fluoren-3-yl)oxy]-N-(pyridin-3-yl)acetamide (7q). Started from **4q** and 3-aminopyridine. Yellow solid, 170 mg, yield = 51%. ¹H NMR (400 MHz, DMSO): δ 10.52 (s, 1H), 8.89 (d, J = 2.4 Hz, 1H), 8.37 (dd, J = 4.8, 1.2 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.81 (d, J = 7.2 Hz, 1H), 7.65-7.55 (m, 3H), 7.53-7.47 (m, 2H), 7.39 (t, J = 7.2 Hz, 1H), 6.95 (dd, J = 8.0, 2.0 Hz, 1H), 4.95 (s, 2H) ppm; HPLC t_R = 6.73 min. purity 99%; ESI-MS: 331.07 [M+H]⁺.

2-[(1-Bromonaphthalen-2-yl)oxy]-N-(pyridin-3-yl)acetamide (7r).²¹ White solid, 235 mg, yield = 74%. ¹H NMR (400 MHz, CDCl₃): δ 9.07 (s br, 1H), 8.77 (d, J = 2.4 Hz, 1H), 8.42 (dd, J = 4.8, 1.2 Hz, 1H), 8.28 (ddd, J = 8.4 Hz, 1.2, 1.2 Hz, 1H), 8.24 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.65 (dd, J = 6.8, 0.8 Hz, 1H), 7.49 (dd, J = 7.2, 0.8 Hz, 1H), 7.34 (dd, J = 8.4, 3.6 Hz, 1H), 7.25 (d, J = 8.4 Hz, 1H), 4.83 (s, 2H); ¹³C NMR (101 MHz, CDCl₃): δ 166.2, 151.2, 145.9, 141.4, 134.0, 132.8, 130.6, 129.8, 128.4, 128.3, 127.0, 126.3, 125.5, 123.8, 114.7, 109.9, 69.0 ppm. HPLC t_R = 7.95 min. purity 99%; ESI-MS: 357.00 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-N-(6-methylpyridin-3-yl)acetamide (7f1). Started from **6f** and 5-amino-2-methylpyridine. White solid, 47 mg, yield = 73%. ¹H NMR (400 MHz, CDCl₃): δ 8.54 (d, J = 2.4 Hz, 1H), 8.35 (s, 1H), 8.07 (dd, J = 8.4, 2.4 Hz, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 7.6 Hz, 1H), 7.43 (td, J = 7.2, 0.8 Hz, 1H), 7.37-7.33 (m, 2H), 7.17 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 4.70 (s, 2H), 2.54 (s, 3H) ppm; HPLC t_R = 7.09 min. purity 99%; ESI-MS: 425.07 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-N-(6-methoxypyridin-3-yl)acetamide (7f2). Started from **6f** and 5-amino-2-methoxypyridine. White solid, 50 mg, yield = 94%. ¹H NMR (400 MHz, CDCl₃): δ 8.31-8.20 (m, 2H), 7.91 (dd, J = 7.8, 2.0 Hz, 1H), 7.83 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 7.6 Hz, 1H), 7.42 (t, J = 7.2 Hz, 1H), 7.37-7.32 (m, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.75 (d, J = 8.8 Hz, 1H), 4.69 (s, 2H), 3.92 (s, 3H) ppm; HPLC t_R = 9.06 min. purity 98%; ESI-MS: 441.07 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-N-(6-chloropyridin-3-yl)acetamide (7f3). Started from **6f** and 5-amino-2-chloropyridine. Yellow solid, 51 mg, yield = 82%. ¹H NMR (400 MHz, CDCl₃): δ 8.47 (d, J = 2.8 Hz, 1H), 8.30 (s, 1H), 8.21 (dd, J = 8.8, 2.8 Hz, 1H), 7.85 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.43-7.32 (m, 4H), 7.05 (d, J = 8.8 Hz, 2H), 4.71 (s, 2H) ppm; HPLC t_R = 9.65 min. purity 100%; ESI-MS: 445.07 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-*N*-(5-methylpyridin-3-yl)acetamide (7f4). Started from **6f** and 3-amino-5-methylpyridine. White solid, 55 mg, yield = 86%. ¹H NMR (400 MHz, CDCl₃): δ 8.47 (d, *J* = 2.0 Hz, 1H), 8.40 (s, 1H), 8.24 (s, 1H), 8.04 (s, 1H), 7.83 (dd, *J* = 7.8, 2.0 Hz, 2H), 7.65 (dd, *J* = 7.2, 0.8 Hz, 1H), 7.43 (td, *J* = 7.0, 1.2 Hz, 1H), 7.37-7.33 (m, 2H), 7.05 (d, *J* = 8.8 Hz, 2H), 4.71 (s, 2H), 2.36 (s, 3H) ppm. HPLC *t*_R = 7.18 min. purity 99%; ESI-MS: 425.07 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-*N*-(5-methoxypyridin-3-yl)acetamide (7f5). Started from **6f** and 3-amino-5-methoxypyridine. White solid, 274 mg, yield = 100%. ¹H NMR (400 MHz, CDCl₃): δ 8.78 (s, 1H), 8.23 (d, *J* = 1.6 Hz, 1H), 8.09 (d, *J* = 2.4 Hz, 1H), 7.90 (t, *J* = 2.4 Hz, 1H), 7.80 (dt, *J* = 9.2, 2.0 Hz, 2H), 7.63 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.41 (td, *J* = 7.8, 1.2 Hz, 1H), 7.34 (td, *J* = 7.8, 2.0 Hz, 1H), 7.30 (dd, *J* = 7.6, 2.0 Hz, 1H), 7.02 (dt, *J* = 8.8, 2.4 Hz, 2H), 4.70 (s, 2H), 3.85 (s, 3H) ppm. HPLC *t*_R = 7.44 min. purity 99%; ESI-MS: 441.07 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-*N*-(4-methylpyridin-3-yl)acetamide (7f6). Started from **6f** and 3-amino-4-methylpyridine. White solid, 90 mg, yield = 70%. ¹H NMR (400 MHz, CDCl₃): δ 8.92 (s, 1H), 8.34 (d, *J* = 4.4 Hz, 1H), 8.28 (s, 1H), 7.84 (d, *J* = 8.8 Hz, 2H), 7.64 (d, *J* = 7.6 Hz, 1H), 7.43 (td, *J* = 7.2, 0.8 Hz, 1H), 7.35 (td, *J* = 7.8, 2.0 Hz, 1H), 7.33 (dd, *J* = 7.4, 2.0 Hz, 1H), 7.16 (d, *J* = 4.8 Hz, 1H), 7.05 (d, *J* = 8.8 Hz, 2H), 4.76 (s, 2H), 2.25 (s, 3H) ppm. HPLC *t*_R = 7.05 min. purity 100%; ESI-MS: 425.13 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-*N*-(4-methoxypyridin-3-yl)acetamide (7f7). Started from **6f** and 3-amino-4-methoxypyridine. Yellow solid, 35 mg, yield = 72%. ¹H NMR (400 MHz, CDCl₃): δ 9.48 (s, 1H), 8.66 (s, 1H), 8.33 (d, *J* = 5.2 Hz, 1H), 7.85 (d, *J* = 8.8 Hz, 2H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.44-7.32 (m, 3H), 7.05 (d, *J* = 8.8 Hz, 2H), 6.85 (d, *J* = 5.6 Hz, 1H), 4.72 (s, 2H), 3.95 (s, 3H) ppm. HPLC *t*_R = 7.13 min. purity 99%; ESI-MS: 441.13 [M+H]⁺.

2-(4-(2-Bromobenzoyl)phenoxy)-*N*-(quinolin-3-yl)acetamide (7f8). Started from **6f** and 3-aminoquinoline. White solid, 44 mg, yield = 83%. ¹H NMR (400 MHz, CDCl₃): δ 8.85 (d, *J* = 2.4 Hz, 1H), 8.79 (s, 1H), 8.60 (s, 1H), 8.06 (d, *J* = 8.4 Hz, 1H), 7.86-7.81 (m, 3H), 7.68-7.63 (m, 2H), 7.55 (t, *J* = 8.0 Hz, 1H), 7.40 (t, *J* = 7.6 Hz, 1H), 7.37-7.31 (m, 2H), 7.07 (d, *J* = 7.6 Hz, 2H), 4.76 (s, 2H) ppm. HPLC *t*_R = 8.10 min. purity 99%; ESI-MS: 461.07 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-*N*-(6-chloropyridazin-3-yl)acetamide (7f9). Started from **6f** and 3-amino-6-chloro-pyridazine. White solid, 32 mg, yield = 6%. ¹H NMR (400 MHz, CDCl₃): δ 9.49 (s, 1H), 8.57 (d, *J* = 8.8 Hz, 1H), 7.86 (d, *J* = 7.6 Hz, 2H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.57 (d, *J* = 9.2 Hz, 1H), 7.43-7.30 (m, 3H), 7.07 (d, *J* = 7.1 Hz, 2H), 4.77 (s, 2H) ppm. HPLC *t*_R = 9.37 min.

purity 97%; ESI-MS: 445.93 [M+H]⁺.

2-[4-(2-Bromobenzoyl)phenoxy]-N-(pyrimidin-5-yl)acetamide (7f10). Started from **6f** and 5-aminopyrimidine. White solid, 24 mg, yield = 26%. ¹H NMR (400 MHz, CDCl₃): δ 9.08 (s, 2H), 9.03 (s, 1H), 8.45 (s, 1H), 7.81 (d, *J* = 8.8 Hz, 2H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.43 (td, *J* = 7.4, 1.2 Hz, 1H), 7.39-7.31 (m, 2H), 7.05 (d, *J* = 8.8 Hz, 2H), 4.75 (s, 2H) ppm. HPLC *t_R* = 8.27 min. purity 99%; ESI-MS: 412.07 [M+H]⁺.

2-(4-(2-Bromobenzoyl)phenoxy)-N-(pyrazin-2-yl)acetamide (7f11). Started from **6f** and 2-aminopyrazine. White solid, 14 mg, yield = 53%. ¹H NMR (400 MHz, CDCl₃) δ 9.62 (s, 1H), 8.87 (s, 1H), 8.43 (s, 1H), 8.31 (s, 1H), 7.85 (dt, *J* = 8.8, 2.0 Hz, 2H), 7.65 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.43 (td, *J* = 7.6, 1.2 Hz, 1H), 7.39-7.32 (m, 2H), 7.06 (dt, *J* = 9.2, 2.8 Hz, 2H), 4.75 (s, 2H) ppm. HPLC *t_R* = 8.68 min. purity 98%; ESI-MS: 412.00 [M+H]⁺.

Biology

Materials and methods

Dofetilide was synthesized in our own laboratory,⁵⁴ and astemizole was purchased from Sigma Aldrich (Zwijndrecht, The Netherlands). Tritium-labeled dofetilide (specific activity 82.3 Ci·mmol⁻¹) was purchased from PerkinElmer (Groningen, The Netherlands). Bovine serum albumin (BSA, fraction V) was purchased from Sigma (St. Louis, MO, USA). G418 was obtained from Stratagene (Cedar Creek, USA). All the other chemicals were of analytical grade and obtained from standard commercial sources. HEK293 cells stably expressing the K_v11.1 channel (HEK293K_v11.1) were kindly provided by Dr. Eckhard Ficker (University of Cleveland, USA).

Cell culture and membrane preparation

HEK293K_v11.1 cells were cultured, and membranes were prepared and stored as described previously.¹⁶

Radioligand kinetic dissociation assays

Kinetic dissociation assays of [³H]dofetilide were performed in incubation buffer (10 mM HEPES, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl₂, 1 mM EGTA, 10 mM glucose, 0.1% BSA, pH 7.4) as described previously with the following modifications.¹⁶ Single point dissociation experiments were conducted by addition of 10 μM dofetilide in the absence (control) or presence of 10 μM synthesized

compounds after preincubation at 25 °C for 2 h. After 6 minutes of dissociation, incubations were terminated by dilution with ice-cold wash buffer (25 mM Tris-HCl, 130 mM NaCl, 60 mM KCl, 0.8 mM MgCl₂, 0.05 mM CaCl₂, 0.05 % BSA, pH 7.4). Separation of bound from free radioligand was performed by rapid filtration through a 96-well GF/B filter plate using a PerkinElmer Filtermate-harvester (PerkinElmer, Groningen, The Netherlands). The filter-bound radioactivity was determined by scintillation spectrometry using the P-E 1450 Microbeta Wallac Trilux scintillation counter (PerkinElmer) after addition of 25 µL Microscint and extraction. Full dissociation assays were carried out with 10 µM dofetilide in the absence (control) or presence of 50 µM selected compounds for a total period of 2 h after preincubation. The amounts of radioligand still bound to the receptor were measured at various time intervals. Concentration-dependent effects of compounds **7f** and **7p** were determined by addition of 10 µM dofetilide in the absence (control) or presence of different concentrations of **7f** and **7p**. After 6 min of dissociation, the incubations were terminated and samples were obtained as described above.

Radioligand displacement assay

[³H]Dofetilide binding assays for the K_v11.1 channel were performed in incubation buffer as described previously.¹⁶ Briefly, membrane aliquots containing 20 µg protein were incubated with 5 nM [³H]dofetilide in a total volume of 100 µl incubation buffer at 25 °C for 1 h. Radioligand displacement experiments were carried out with various concentrations of tested compounds. Total binding was determined in the presence of incubation buffer, whereas nonspecific binding was evaluated with 10 µM astemizole. Incubations were terminated by dilution with ice-cold wash buffer, and samples were obtained as described in the “*radioligand kinetic dissociation assays*”. The displacement assays of dofetilide and astemizole were conducted in the absence (control) or presence of 10 µM **7f**, **7h-j** and **7p**.

Data analysis

All data of radioligand binding assays were analyzed with Prism v. 5.0 (Graph-Pad, San Diego, CA, USA). Dissociation rate constants, k_{off} , were obtained by computer analysis of the exponential decay of [³H]dofetilide bound to the K_v11.1 channel. EC₅₀ values from kinetic dissociation assays were calculated by non-linear regression analysis of concentration-effect curves of dissociation in the presence of different concentrations of unlabeled ligands. IC₅₀ values in displacement assays were directly obtained from non-linear regression analysis of dose-re-

sponse curves. Apparent inhibitory binding constants (K_i values) were derived from the IC_{50} values according to the Cheng-Prusoff relationship:⁵⁵ $K_i = IC_{50}/(1 + [L^*]/K_D)$, where $[L^*]$ is the concentration of radioligand and K_D its dissociation constant from the saturation assay.³⁰ All values obtained from radioligand binding assays in this study are means of at least three independent experiments performed in duplicate, and data are presented as mean $\pm$ SEM. Statistical analysis was performed with a two-tailed unpaired Student's t-test.

References

1. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors. *Ann. Rev. Pharm. Toxicol.* **2007**, *47*, 1-51.
2. Hogg, R. C.; Buisson, B.; Bertrand, D. Allosteric modulation of ligand-gated ion channels. *Biochem. Pharmacol.* **2005**, *70*, 1267-1276.
3. Lewis, J. A.; Lebois, E. P.; Lindsley, C. W. Allosteric modulation of kinases and GPCRs: Design principles and structural diversity. *Curr. Opin. Chem. Biol.* **2008**, *12*, 269-280.
4. Christopoulos, A.; Changeux, J.-P.; Catterall, W. A.; Fabbro, D.; Burris, T. P.; Cidlowski, J. A.; Olsen, R. W.; Peters, J. A.; Neubig, R. R.; Pin, J.; Sexton, P. M.; Kenakin, T. P.; Ehlert, F. J.; Spedding, M.; Langmead, C. J. International union of basic and clinical pharmacology. XC. multisite pharmacology: Recommendations for the nomenclature of receptor allosterism and allosteric ligands. *Pharmacol. Rev.* **2014**, *66*, 918-947.
5. Davey, A. E.; Leach, K.; Valant, C.; Conigrave, A. D.; Sexton, P. M.; Christopoulos, A. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. *Endocrinol.* **2011**, *153*, 1232-1241.
6. Sanguinetti, M. C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. *Nature* **2006**, *440*, 463-469.
7. Vandenberg, J. I.; Perry, M. D.; Perrin, M. J.; Mann, S. A.; Ke, Y.; Hill, A. P. hERG K^+ channels: Structure, function, and clinical significance. *Physiol. Rev.* **2012**, *92*, 1393-1478.
8. Xu, X.; Recanatini, M.; Roberti, M.; Tseng, G.-N. Probing the binding sites and mechanisms of action of two human ether-à-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243). *Mol. Pharmacol.* **2008**, *73*, 1709-1721.
9. Perry, M.; Sanguinetti, M.; Mitcheson, J. Revealing the structural basis of action of hERG potassium channel activators and blockers. *J. Physiol. (Lond.)* **2010**, *588*, 3157-3167.
10. Ravens, U. Novel pharmacological approaches for antiarrhythmic therapy. *Naunyn*

Schmiedebergs Arch. Pharmacol. **2010**, 381, 187-193.

11. Grunnet, M.; Hansen, R. S.; Olesen, S.-P. hERG1 channel activators: A new anti-arrhythmic principle. *Prog. Biophys. Mol. Biol.* **2008**, 98, 347-362.
12. Kang, J.; Chen, X.; Wang, H.; Ji, J.; Cheng, H.; Incardona, J.; Reynolds, W.; Viviani, F.; Tabart, M.; Rampe, D. Discovery of a small molecule activator of the human ether-à-go-go-related gene (hERG) cardiac K⁺ channel. *Mol. Pharmacol.* **2005**, 67, 827-836.
13. Perry, M.; Sachse, F. B.; Sanguinetti, M. C. Structural basis of action for a human ether-à-go-go-related gene 1 potassium channel activator. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, 104, 13827-13832.
14. Durdagi, S.; Guo, J.; Lees-Miller, J. P.; Noskov, S. Y.; Duff, H. J. Structure-guided topographic mapping and mutagenesis to elucidate binding sites for the human ether-à-go-go-related gene 1 potassium channel (KCNH2) activator NS1643. *J. Pharmacol. Exp. Ther.* **2012**, 342, 441-452.
15. Hansen, R. S.; Olesen, S.-P.; Rønn, L. C. B.; Grunnet, M. *In vivo* effects of the I_{Kr} agonist NS3623 on cardiac electrophysiology of the guinea pig. *J. Cardiovasc. Pharmacol.* **2008**, 52, 35-41.
16. Yu, Z.; Klaasse, E.; Heitman, L. H.; IJzerman, A. P. Allosteric modulators of the hERG K⁺ channel: Radioligand binding assays reveal allosteric characteristics of dofetilide analogs. *Toxicol. Appl. Pharmacol.* **2014**, 274, 78-86.
17. Seeböhm, G. Activators of cation channels: Potential in treatment of channelopathies. *Mol. Pharmacol.* **2005**, 67, 585-588.
18. Zhang, H.; Zou, B.; Yu, H.; Moretti, A.; Wang, X.; Yan, W.; Babcock, J. J.; Bellin, M.; McManus, O. B.; Tomaselli, G.; Nan, F.; Laugwitz, K. L.; Li, M. Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. *Proc. Natl. Acad. Sci. U.S.A.* **2012**, 109, 11866-11871.
19. Diness, T. G.; Yeh, Y.-H.; Qi, X. Y.; Chartier, D.; Tsuji, Y.; Hansen, R. S.; Olesen, S.-P.; Grunnet, M.; Nattel, S. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. *Cardiovasc. Res.* **2008**, 79, 61-69.
20. Xu, X.; Salata, J. J.; Wang, J.; Wu, Y.; Yan, G.; Liu, T.; Marinchak, R. A.; Kowey, P. R. Increasing I_{Ks} corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy. *Am. J. Physiol. Heart Circ. Physiol.* **2002**, 283, H664-H670.
21. Potet, F.; Lorinc, A. N.; Chaigne, S.; Hopkins, C. R.; Venkataraman, R.; Stepanovic, S. Z.; Lewis, L. M.; Days, E.; Sidorov, V. Y.; Engers, D. W.; Zou, B.; Afshartous, D.; George, A. L.; Campbell, C. M.; Balser, J. R.; Li, M.; Baudenbacher, F. J.; Lindsley, C. W.; Weaver, C. D.; Kupersmidt, S. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias. *J. Biol. Chem.* **2012**, 287, 39613-39625.

22. Ruenitz, P. C.; Bourne, C. S.; Sullivan, K. J.; Moore, S. A. Estrogenic triarylethylene acetic acids: Effect of structural variation on estrogen receptor affinity and estrogenic potency and efficacy in MCF-7 cells. *J. Med. Chem.* **1996**, *39*, 4853-4859.
23. Breyer, S.; Semmler, A.; Miller, T.; Hill, A.; Geissler, S.; Haberkorn, U.; Mier, W. Radioiodinated dechloro-4-iodofenofibrate: A hydrophobic model drug for molecular imaging studies. *Int. J. Pharm* **2012**, *431*, 78-83.
24. Li, H.; Zhu, R.; Shi, W.; He, K.; Shi, Z. Synthesis of fluorenone derivatives through Pd-catalyzed dehydrogenative cyclization. *Org. Lett.* **2012**, *14*, 4850-4853.
25. Li, B.; Magee, T. V.; Buzon, R. A.; Widlicka, D. W.; Bill, D. R.; Brandt, T.; Cao, X.; Coutant, M.; Dou, H.; Granskog, K. Process development of a novel azetidiny ketolide antibiotic. *Org. Process Res. Dev.* **2012**, *16*, 788-797.
26. Kostenis, E.; Mohr, K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. *Trends Pharmacol. Sci.* **1996**, *17*, 280-283.
27. Kalinichev, M.; Donovan-Rodriguez, T.; Girard, F.; Riguet, E.; Rouillier, M.; Bour-nique, B.; Haddouk, H.; Mutel, V.; Poli, S. Evaluation of peripheral versus central effects of GABA_B receptor activation using a novel, positive allosteric modulator of the GABA_B receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile. *Br. J. Pharmacol.* **2014**, *171*, 4941-4954.
28. Gao, Z.; Van Muijlwijk-Koezen, J. E.; Chen, A.; Müller, C. E.; IJzerman, A. P.; Jacobson, K. A. Allosteric modulation of A₃ adenosine receptors by a series of 3-(2-pyr-idinyl) isoquinoline derivatives. *Mol. Pharmacol.* **2001**, *60*, 1057-1063.
29. van den Nieuwendijk, A. M.; Pietra, D.; Heitman, L.; Göblyös, A.; IJzerman, A. P. Synthesis and biological evaluation of 2, 3, 5-substituted [1, 2, 4] thiadiazoles as al-losteric modulators of adenosine receptors. *J. Med. Chem.* **2004**, *47*, 663-672.
30. Yu, Z.; IJzerman, A.; Heitman, L. K_v11.1 (hERG)-induced cardiotoxicity: A molec-ular insight from a binding kinetics study of prototypic K_v11.1 (hERG) inhibitors. *Br. J. Pharmacol.* **2015**, *172*, 940-945.
31. Szabo, G.; Farkas, V.; Grunnet, M.; Mohacsi, A.; P Nanasi, P. Enhanced repolariza-tion capacity: New potential antiarrhythmic strategy based on HERG channel activation. *Curr. Med. Chem.* **2011**, *18*, 3607-3621.
32. Moorthy, J. N.; Samanta, S. Photoinduced C-Br homolysis of 2-bromobenzophe-ones and pschorr ring closure of 2-aryolaryl radicals to fluorenones. *J. Org. Chem.* **2007**, *72*, 9786-9789.
33. Shimizu, Y.; Izumi, S.; Takenaka, J.; Momoda, J. Chromene compound and curable composition. In Google Patents: 2012.
34. Babu, S. A.; Yasuda, M.; Baba, A. In (III)-mediated chemoselective dehydroge-native interaction of ClMe₂SiH with carboxylic acids: Direct chemo-and regioselective Friedel-Crafts acylation of aromatic ethers. *Org. Lett.* **2007**, *9*, 405-408.
35. Liao, Y.; Hu, Q. Aryl ketone synthesis via tandem orthoplatinated triarylphos-

- phite-catalyzed addition reactions of arylboronic acids with aldehydes followed by oxidation. *J. Org. Chem.* **2010**, *75*, 6986-6989.
36. Sui, Y.; Zhang, X.; Wu, J.; Li, S.; Zhou, J.; Li, M.; Fang, W.; Chan, A. S.; Wu, J. Cu^{II}-catalyzed asymmetric hydrosilylation of diaryl- and aryl heteroaryl ketones: Application in the enantioselective synthesis of orphenadrine and neobenodine. *Chem. Eur. J.* **2012**, *18*, 7486-7492.
37. Aziz, J.; Frison, G.; Le Menez, P.; Brion, J.-D.; Hamze, A.; Alami, M. Gold versus palladium: A regioselective cycloisomerization of aromatic enynes. *Adv. Synth. Catal.* **2013**, *355*, 3425-3436.
38. Wang, X.; Liu, F.; Tu, H.; Zhang, A. One-pot synthesis of diarylmethanones through palladium-catalyzed sequential coupling and aerobic oxidation of aryl bromides with acetophenone as a latent carbonyl donor. *J. Org. Chem.* **2014**, *79*, 6554-6562.
39. Sarvari, M. H.; Sharghi, H. Solvent-free catalytic friedel-crafts acylation of aromatic compounds with carboxylic acids by using a novel heterogeneous catalyst System: *p*-Toluenesulfonic acid/Graphite. *Helv. Chim. Acta* **2005**, *88*, 2282-2287.
40. Gan, Y.; Blank, D. H.; Ney, J. E.; Spencer, T. A. Nonsteroidal benzophenone-containing analogues of cholesterol. *J. Org. Chem.* **2006**, *71*, 5864-5869.
41. Cowart, M.; Faghih, R.; Curtis, M. P.; Gfesser, G. A.; Bennani, Y. L.; Black, L. A.; Pan, L.; Marsh, K. C.; Sullivan, J. P.; Esbenshade, T. A.; Fox, G. B.; Hancock, A. A. 4-(2-[2-(2 (*R*)-methylpyrrolidin-1-yl)ethyl] benzofuran-5-yl) benzonitrile and related 2-aminoethylbenzofuran H₃ receptor antagonists potently enhance cognition and attention. *J. Med. Chem.* **2005**, *48*, 38-55.
42. Böger, M.; Dürr, D.; Gsell, L.; Hall, R. G.; Karrer, F.; Kristiansen, O.; Maienfisch, P.; Pascual, A.; Rindlisbacher, A. Synthesis and structure-activity relationships of benzophenone hydrazone derivatives with insecticidal activity. *Pest Manag. Sci.* **2001**, *57*, 191-202.
43. Williams, D. L.; Ronzion, A. R. A contribution to the total synthesis of alizarin¹. Synthesis of 1, 2-dihydroxy-9, 10-anthraquinone-9-C¹⁴. *J. Org. Chem.* **1953**, *18*, 489-495.
44. Sasse, A.; Ligneau, X.; Sadek, B.; Elz, S.; Pertz, H. H.; Ganellin, C. R.; Arrang, J.-M.; Schwartz, J.-C.; Schunack, W.; Stark, H. Benzophenone derivatives and related compounds as potent histamine H₃-receptor antagonists and potential PET/SPECT ligands. *Arch. Pharm.* **2001**, *334*, 45-52.
45. Bao, X.; Jin, Y.; Liu, X.; Liao, H.; Zhang, L.; Pang, T. Synthesis and biological evaluation of XB-1 analogues as novel histamine H₃ receptor antagonists and neuroprotective agents. *RSC Adv.* **2014**, *4*, 6761-6775.
46. Sudha, B.; Shashikanth, S.; Ara Khanum, S. Synthesis of 5-(4'-aroyl)-aryloxy methyl-4*H*-(1, 2, 4)-triazolin-3-thiol and their biological activity. *Heterocycl. Comm.* **2004**, *10*, 85-88.
47. Nakatani, K.; Dohno, C.; Saito, I. Synthesis of DNA oligomers containing modified

- uracil possessing electron-accepting benzophenone chromophore. *J. Org. Chem.* **1999**, *64*, 6901-6904.
48. Atkinson, G. E.; Fischer, P. M.; Chan, W. C. A versatile polymer-supported 4-(4-methylphenyl (chloro) methyl) phenoxy linker for solid-phase synthesis of pseudo-peptides. *J. Org. Chem.* **2000**, *65*, 5048-5056.
49. Sundstrom, G. Metabolic hydroxylation of the aromatic rings of 1, 1-dichloro-2, 2-bis (4-chlorophenyl) ethylene (p, p'-DDE) by the rat. *J. Agric. Food Chem.* **1977**, *25*, 18-21.
50. Soper, Q. F.; Whitehead, C. W.; Behrens, O. K.; Corse, J. J.; Jones, R. G. Biosynthesis of penicillins. VII.¹ Oxy-and mercaptoacetic acids. *J. Am. Chem. Soc.* **1948**, *70*, 2849-2855.
51. Giampietro, L.; Angelo, A.; Giancristofaro, A.; Ammazalorso, A.; De Filippis, B.; DiMatteo, M.; Fantacuzzi, M.; Linciano, P.; Maccallini, C.; Amoroso, R. Effect of stilbene and chalcone scaffolds incorporation in clofibric acid on PPAR α agonistic activity. *Med. Chem.* **2014**, *10*, 59-65.
52. Alewood, D.; Hopping, G.; Brust, A.; Reid, R. C.; Alewood, P. F. Benzhydrylamine linker grafting: A strategy for the improved synthesis of C-terminal peptide amides. *J. Pept. Sci.* **2010**, *16*, 551-557.
53. Massolini, G.; Carmellino, M.; Baruffini, A. Some derivatives of 4-(p. chlorobenzoyl) phenol were prepared and tested for phytoiatric antimycotic activity. *Farm. Ed. Sci.* **1986**, *41*, 381-387.
54. Shagufta; Guo, D.; Klaasse, E.; de Vries, H.; Brussee, J.; Nalos, L.; Rook, M. B.; Vos, M. A.; van der Heyden, M. A.; IJzerman, A. P. Exploring Chemical Substructures Essential for hERG K⁺ Channel Blockade by Synthesis and Biological Evaluation of Dofetilide Analogues. *ChemMedChem* **2009**, *4*, 1722-1732.
55. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (I_{50}) of an enzymatic reaction. *Biochem. Pharmacol.* **1973**, *22*, 3099-3108.